1 Large-scale integration of omics and electronic health records to identify potential 2 risk protein biomarkers and therapeutic drugs for cancer prevention and intervention 3 4 Qing Li^{1,2†}, Qingyuan Song^{3,4,†}, Zhishan Chen^{1,†}, Jungyoon Choi⁵, Victor Moreno^{6,7,8,9}, Jie Ping¹, Wanging Wen¹, Chao Li¹, Xiang Shu¹⁰, Jun Yan¹¹, Xiao-ou Shu¹, Qiuyin Cai¹, Jirong 5 Long¹, Jeroen R Huyghe¹², Rish Pai¹³, Stephen B Gruber¹⁴, Graham Casey¹⁵, Xusheng 6 7 Wang¹⁶, Adetunji T. Toriola¹⁷, Li Li¹⁸, Bhuminder Singh¹⁹, Ken S Lau¹⁹, Li Zhou²⁰, Chong Wu²¹, Ulrike Peters^{12,22}, Wei Zheng¹, Quan Long^{2,23,24,25,26*}, Zhijun Yin^{3,4*}, Xingyi Guo^{1,3*} 8 9 10 Affiliations: 11 ¹ Division of Epidemiology, Department of Medicine, Vanderbilt Epidemiology Center, 12 Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, TN, 13 USA 14 ² Department of Biochemistry and Molecular Biology, University of Calgary, Calgary, Alberta, 15 Canada ³ Department of Biomedical Informatics, Vanderbilt University School of Medicine, Nashville, 16 17 TN, USA 18 ⁴ Department of Department of Computer Science, Vanderbilt University, Nashville, TN, USA 19 ⁵ Division of Oncology and Hematology, Department of Internal Medicine, Korea University 20 Ansan Hospital, Korea University College of Medicine, Ansan 15355, Korea 21 ⁶ Oncology Data Analytics Program, Catalan Institute of Oncology (ICO), L'Hospitalet de 22 Llobregat, Barcelona, Spain 23 ⁷ Colorectal Cancer Group, ONCOBELL Program, Institut de Recerca Biomedica de 24 Bellvitge (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain 25 ⁸ Department of Clinical Sciences, Faculty of Medicine and health Sciences and Universitat 26 de Barcelona Institute of Complex Systems (UBICS), University of Barcelona (UB), 27 L'Hospitalet de Llobregat, Barcelona, Spain 28 ⁹ Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), 29 Madrid, Spain 30 ¹⁰ Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, 31 New York, NY, USA 32 ¹¹ Physiology and Pharmacology, University of Calgary, Calgary, Alberta, Canada 33 ¹² Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA, 34 USA ¹³ Mayo Clinic Arizona, Scottsdale, AZ, USA. 35 ¹⁴ Department of Preventive Medicine & USC Norris Comprehensive Cancer Center, Keck 36 NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. School of Medicine, University of Southern California, Los Angeles, CA, USA 37

- ¹⁵ Center for Public Health Genomics, University of Virginia, Charlottesville, VA, USA
- ¹⁶ Department of Genetics, Genomics and Informatics, University of Tennessee Health
- 40 Science Center, Memphis, TN, USA
- 41 ¹⁷ Division of Public Health Sciences, Department of Surgery, Washington University School
- 42 of Medicine and Siteman Cancer Center, St. Louis, MO, USA
- ⁴³ ¹⁸ Department of family medicine, School of Medicine, University of Virginia, Charlottesville,
- 44 VA, USA
- ⁴⁵ ¹⁹ Epithelial Biology Center and Department of Cell and Developmental Biology, Vanderbilt
- 46 University School of Medicine, Nashville, TN, USA
- 47 ²⁰ Harvard Medical School, Boston, Massachusetts; Division of General Internal Medicine
- 48 and Primary Care, Department of Medicine, Brigham and Women's Hospital, Boston,
- 49 Massachusetts.
- 50 ²¹ Department of Biostatistics, the University of Texas MD Anderson, Houston, Texas, USA
- 51 ²² Department of Epidemiology, University of Washington School of Public Health, Seattle,
- 52 WA, USA
- ²³ Department of Medical Genetics, Cumming School of Medicine, University of Calgary,
- 54 Calgary, Alberta, Canada
- ²⁴ The Mathison Centre for Mental Health Research & Education, Hotchkiss Brain Institute,
- 56 Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada
- ²⁵ Alberta Children's Hospital Research Institute, Cumming School of Medicine, University of
- 58 Calgary, Calgary, Alberta, Canada
- ²⁶ Department of Mathematics and Statistics, Faculty of Science, University of Calgary,
- 60 Calgary, Alberta, Canada
- 61
- 62 [†]Author names shared co-first authorship
- 63 *Corresponding authors
- 64
- 65 Dr. Xingyi Guo
- 66 Division of Epidemiology, Department of Medicine, Vanderbilt Epidemiology Center, and
- 67 Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine
- 68 2525 West End Ave. Suite 330, Nashville, TN 37203
- 69 Tel: +1 615-936-3471; Fax: +1 615-332-0502
- 70 Email: <u>xingyi.guo@vumc.org</u>
- 71
- 72 Dr. Zhijun Yin
- 73 Department of Biomedical Informatics, Department of Computer Science
- 74 Vanderbilt University Medical Center

- 75 2525 West End Ave. Suite 1475, Nashville, TN 37203
- 76 Tel: +1 615-936-3690; Fax: +1 615-322-0102
- 77 Email: zhijun.yin.1@vumc.org
- 78

79 Dr. Quan Long

- 80 Department of Biochemistry and Molecular Biology,
- 81 University of Calgary,
- 82 3330 Hospital Drive NW
- 83 Room 1151 (1173), Health Sciences Centre
- 84 Calgary, AB T2N 4N1 Canada
- 85 Tel: 403-220-5580; Fax: 403-210-9538
- 86 Email: <u>quan.long@ucalgary.ca</u>

87 Abstract

- 88 Identifying risk protein targets and their therapeutic drugs is crucial for effective cancer
- 89 prevention. Here, we conduct integrative and fine-mapping analyses of large genome-wide
- 90 association studies data for breast, colorectal, lung, ovarian, pancreatic, and prostate
- 91 cancers, and characterize 710 lead variants independently associated with cancer risk.
- 92 Through mapping protein quantitative trait loci (pQTL) for these variants using plasma
- 93 proteomics data from over 75,000 participants, we identify 365 proteins associated with
- 94 cancer risk. Subsequent colocalization analysis identifies 101 proteins, including 74 not
- 95 reported in previous studies. We further characterize 36 potential druggable proteins for
- 96 cancers or other disease indications. Analyzing >3.5 million electronic health records, we
- 97 uncover five drugs (Haloperidol, Trazodone, Tranexamic Acid, Haloperidol, and Captopril)
- 98 associated with increased cancer risk and two drugs (Caffeine and Acetazolamide) linked to
- 99 reduced colorectal cancer risk. This study offers novel insights into therapeutic drugs
- 100 targeting risk proteins for cancer prevention and intervention.

101 Introduction

102

103 Human genetic research has not only advanced our understanding of disease 104 mechanisms but has also significantly contributed to drug discovery and development. Drugs 105 supported by genetic evidence exhibit enhanced therapeutic validity compared to those 106 lacking such support, highlighting the importance of incorporating genetic evidence in drug 107 development initiatives^{1,2}. Common risk variants implicated in diseases can dysregulate 108 nearby gene or protein expression, which can mimic the effects of therapeutic drugs on the 109 targetable proteins. These proteins could serve as potential targets for therapeutic 110 intervention³. Thus, concerted efforts for cancer prevention based on proteins influenced by 111 common polymorphisms that modulate cancer risk, are urgently needed⁴. To date, genome-112 wide association studies (GWAS) have identified several hundred common genetic risk loci 113 for each of three prevalent cancer types: breast, colorectal, and prostate⁵⁻⁸, and several 114 dozen risk loci have been identified for other cancers, such as cancer of lung, pancreas, and 115 ovarian⁹⁻¹³. Previous research, including our work, has identified hundreds of putative 116 cancer susceptible genes potentially regulated by these risk variants, using methods such as expression quantitative trait loci (eQTL) analysis^{8-12,14-20} and transcriptome-wide association 117 118 studies (TWAS)^{7,19,21-29}. However, most dysregulated gene expression has not been 119 thoroughly investigated at the protein level.

120

121 To deepen the understanding of causal mechanisms and enhance drug discovery 122 endeavors, it is imperative to explore data from transcriptomic to proteomic studies. Proteins, 123 the ultimate products of mRNA translation, play critical roles in cellular activities and 124 represent promising therapeutic targets, as evidenced by successful drug targeting of enzymes, transporters, ion channels, and receptors³⁰. Recent studies include protein 125 126 quantitative trait loci (pQTL) mapping and Mendelian randomization (MR) analysis by 127 integrating cancer GWAS and blood proteomics data to identify potential risk proteins. 128 However, only a few dozen of cancer risk proteins have been reported, with a false 129 discovery rate $< 0.05^{31-36}$. Most reported proteins have not been directly linked to the GWAS-130 identified risk variants in common cancer types. Furthermore, research is lacking in 131 integrating multiple population-scale proteomic studies like the recent emerging UK Biobank 132 Pharma Proteomics Project (UKB-PPP)³⁷, which offers an unprecedented opportunity to 133 establish extensive pQTL databases, accelerating therapeutic drug discovery for therapeutic 134 prevention and intervention in human cancers. 135

Traditional drug discovery faces numerous challenges, including escalating costs,
 lengthy timelines, and high failure rates³⁸. Drug repurposing presents a promising strategy

by identifying new applications for existing drugs, leveraging their well-documented
characteristics³⁹. With the widespread adoption of modern electronic health record (EHR)
systems, vast amounts of real-world patient data are available to augment pre-clinical
outcomes and facilitate drug repurposing screening. Recently, drug repurposing using EHRs

has successfully discovered repurposing hypotheses for preventing Alzheimer's Disease⁴⁰,

143 reducing cancer mortality^{41,42}, treating COVID-19^{43,44}, and coronary artery disease⁴⁵.

144 However, for therapeutic drugs that have been used for a long term to treat disease

145 indications with evidence of affecting the expression of cancer risk proteins, their potential

association with the risk of human cancers remains largely unclear. Some of these drugs

147 may be linked to an increased cancer risk due to long-neglected side effects.

148

149 In this work, we integrate large GWAS data for breast, colorectal, lung, ovarian, 150 pancreatic, and prostate cancers and population-scale proteomics data from over 75,000 151 participants combined from Atherosclerosis Risk in Communities study (ARIC)⁴⁶, deCODE 152 genetics⁴⁷, and UKB-PPP to identify risk proteins associated with each cancer. We further 153 characterized therapeutic drugs based on druggable risk proteins targeted by approved 154 drugs or undergoing clinical trials for cancer treatment or other indications. We further 155 evaluate the effect of cancer risk for those drugs approved for the indications, using over 3.5 156 million EHR database at Vanderbilt University Medical Center (VUMC). Findings from this 157 study offer novel insights into therapeutic drugs targeting risk proteins for cancer prevention 158 and intervention.

159

160 **Results**

161 **Overall analysis workflow**

162 In Figure 1, we outlined several main steps of a comprehensive integrative analysis 163 of GWAS, pQTLs, druggable proteins, and EHR data. First, we examined previously 164 identified risk loci from six cancer types based on the most recent GWAS in breast (N = 165 247,173), ovary (N = 63,347), prostate (N = 140,306), colorectum (N = 254,791), lung (N = (N = 140, 306)), colorectum (N = 254,791), lung (N = (N = 140, 306)), colorectum (N = (N = 140,166 85.716), and pancreas (N = 21.536). Through additional fine-mapping analysis using 167 SuSiE⁴⁸, we characterized the most significantly associated variants (the lead variants) with 168 independent association signals at each risk locus for each cancer (Fig. 1a; Online 169 Methods). Second, we analyzed *cis*-pQTL results for the lead variants using proteomics data from individuals of European descent from ARIC⁴⁶, deCODE⁴⁷, and UKB-PPP³⁷. We 170 conducted fixed-effect meta-analyses of summary statistics *cis*-pQTLs from ARIC⁴⁶ and 171 deCODE⁴⁷ through the same SOMAscan[®] platform (covering > 4,500 proteins). We 172

173 combined them with the pQTL results from UKB-PPP through the Olink platform to identify 174 potential risk proteins. For proteins that satisfied the significance threshold after multiple 175 testing corrections, we further performed colocalization analyses to determine cancer risk 176 proteins with high confidence through evaluating the likelihood of shared causal variants 177 between pQTLs and GWAS (Fig. 1a). Third, these risk proteins with evidence of 178 colocalization were further annotated based on drug-protein information from four 179 drugs/compounds databases (DrugBank⁴⁹, ChEMBL⁵⁰, the Therapeutic Target Database⁵¹ 180 (TTD) and OpenTargets⁵² (Fig. 1b). We next identified druggable proteins that are 181 therapeutic targets of approved drugs or undergoing clinical trials for cancer treatment or 182 other indications. Finally, we focused on drugs approved for other indications. We built emulation of treated-control drug trials under the Inverse Probability of Treatment weighting 183 184 (IPTW) framework⁵³ through the analysis of over 3.5 million EHRs at VUMC. In these 185 emulations, we used the Cox proportional hazard model for each trial to evaluate the hazard 186 ratio (HR) of the specific cancer risk between the treated focal drug and the control drug. 187 The significance of each focal drug (HR and P value) was derived from a random-effects 188 meta-analysis of results across its balanced trials (Fig. 1c, Online Methods).

189

190 Characterizing lead variants for breast, ovarian, prostate, colorectal, lung, and

191 pancreas cancers

192 To characterize lead variants at each locus for each cancer type, we collected the 193 reported risk variants from previous fine-mapping or GWAS. Using breast cancer as an 194 example, we included 196 lead variants with independent association signals at loci from a previous fine-mapping study based on conditional association analysis⁵⁴ and additional 32 195 genetic variants identified from a recent GWAS⁶. We then performed additional fine-mapping 196 197 analysis using SuSiE⁴⁸ based on summary statistics of GWAS (N = 247,173) from the Breast 198 Cancer Association Consortium (BCAC, Supplementary Table 1). After integrating the 199 previous results with new fine-mapping efforts, we identified 227 lead variants with 200 independently associated with cancer risk at each locus through several processing steps, which included lead variant selection ($P < 1 \times 10^{-6}$ in European populations) and evaluating a 201 202 linkage disequilibrium (LD) ($r^2 < 0.1$) among the identified risk variants (**Extended Data Fig.** 203 1; Online Methods). Similarly, we characterized lead variants from previous GWAS and our fine-mapping studies for colorectal⁵⁵ and other cancers (Extended Data Fig. 1; 204 205 Supplementary Table 1; Online Methods). In our analysis, we identified 710 lead variants, 206 including 227 for breast cancer, 213 for colorectal cancer, 213 for prostate cancer, 26 for 207 lung cancer, 13 for ovarian cancer and 18 for pancreatic cancer (Fig. 2 and Supplementary 208 Tables 2 and 3; Online Methods).

209

210 Identifying cancer risk proteins from pQTLs mapping and colocalization analyses

211 We mapped the 710 lead variants to *cis*-pQTLs to identify cancer risk proteins. At a 212 Bonferroni-corrected P < 0.05, we identified a total of 459 pQTL association signals 213 (corresponding 365 proteins after combined proteins unique for each cancer) for 222 lead 214 variants across six cancer types, including 74 for breast, 127 for colorectal, 37 for lung, 5 for 215 ovarian, 9 for pancreatic, and 113 for prostate cancer (Fig. 2; Supplementary Table 4). 216 Notably, 312 of the identified proteins (85.4% of 365) among these cancer types have not 217 been reported in previous proteomics-based MR studies^{32-36,56,57} (Supplementary Table 5). 218 Furthermore, through analysis of the identified proteins commonly observed in multiple 219 cancers, we found that 60 proteins were commonly observed in at least two of these six 220 cancers. In particular, we observed that several well-known cancer-related proteins, such as HLA-A and HLA-E, were linked to lead variants located in major histocompatibility complex 221 222 (MHC) in breast, colorectal and lung cancers, highlighting the potential role of these proteins 223 in cancer pleiotropy and shared cancer risk mechanisms (Fig. 2).

224

225 A further colocalization analysis identified 101 proteins after combined proteins 226 unique for each cancer that showed strong evidence supported by either colocalization or 227 SMR+HEIDI analysis (Online Methods). Specifically, we identified 23 proteins for breast, 38 228 proteins for colorectal cancer, 7 proteins for lung, 2 for ovarian, 2 for pancreatic and 29 for 229 prostate cancer, respectively (Fig. 3a-b, Supplementary Table 6). Of these, 74 proteins 230 (73.2% of 101) have not been previously linked to cancer risk (Supplementary Table 7). Of 231 note, 71 proteins were only assayed by either SOMAscan[®] (n=32) or Olink platform (n=39). 232 For the remaining 22 significant proteins commonly assayed, all showed a pQTL significance signal with a minimal nominal $P < 1 \times 10^{-5}$ in both ARIC+deCODE and UKB-PPP (r = 0.66, P 233 234 = 2×10^{-4} ; Fig. 3c). In particular, seven proteins were highlighted as cancer-driver proteins^{58,59} 235 and Cancer Gene Census (CGC)⁶⁰, including ALDH2, HLA-A and SUB1 for breast cancer, 236 ALDH2 and HLA-A for colorectal cancer, NT5C2 for lung cancer, and NT5C2, RNF43, 237 TYRO3 and USP28 for prostate cancer.

238

239 Cancer risk proteins supported by functional genomics analyses

Of the identified 101 proteins among the six cancers, we next examined whether they are supported by functional genomics analyses. Specifically, we first evaluated xQTL (i.e., eQTLs, alternative splicing - sQTLs, and alternative polyadenylation - apaQTLs) results in their respective target tissues and whole blood samples (**Online Methods**). We found 63 proteins that were supported by at least one xQTLs at a nominal P < 0.05, including12 for breast (52% of 23), 22 for colorectal (57% of 38), 5 for lung (71% of 7), 2 for ovarian, 2 for pancreatic, and 20 (68% of 29) for prostate cancer (**Supplementary Table 7**). Second, we

247 used functional genomic data generated in their cancer-related tissues/cells (i.e., promoter 248 and enhancer) to characterize putative functional variants that are in strong LD ($r^2 > 0.8$ in 249 the European population) with the lead variants (Online Methods) Our results showed that 250 17 genes were likely regulated by the closest putative regulatory variants with either 251 promoter and/or enhancer activities (Supplementary Table 8). We further investigated the 252 potential distal regulatory effects of putative functional variants on these genes by analyzing 253 chromatin-chromatin interaction data (Online Methods). We found that 39 genes were 254 regulated distally by putative functional variants through long-term promoter-enhancer 255 interactions (Supplementary Table 9). Lastly, we examined differential protein expression 256 between normal and tumor tissues available for breast, colon, lung and pancreatic cancers 257 using data from Clinical Proteomic Tumor Analysis Consortium (CPTAC). We showed 258 evidence of the 18 identified proteins with consistent association directions supported by 259 significantly differential expression at a nominal P < 0.05, including 3 for breast cancer, 10 260 for colorectal cancer, 4 for lung cancer and 1 for pancreatic cancer. Similarly, we showed 261 evidence of the 40 identified proteins supported by significantly differential mRNA expression 262 using data from The Cancer Genome Atlas Program (TCGA), including 6 for breast cancer, 263 15 for colorectal cancer, 3 for lung cancer, 1 for pancreatic cancer and 15 for prostate 264 cancer. Taken together, our analysis provided additional evidence that most of the identified 265 proteins partially or wholly supported by functional genomics analyses (Supplementary 266 Table 10).

267

268 Identifying druggable proteins

Using data from DrugBank⁴⁹, ChEMBL⁵⁰, the Therapeutic Target Database⁵¹ (TTD) 269 270 and OpenTargets⁵², we comprehensively annotated our proteins as therapeutic targets of 271 approved or clinical-stage drugs (Online Methods). Of the 101 proteins among the six 272 cancers, we identified 36 druggable proteins potentially targeted by 404 approved drugs or 273 undergoing clinical trials for cancer treatment or other indications (Fig. 4, Supplementary 274
 Table 11). Specifically, we found 19 proteins targeted by 133 drugs either approved or under
 clinical trials to treat cancers (Fig. 5, Supplementary Table 12). Our results also provide 275 276 evidence that the remaining draggable proteins are targeted by 197 drugs used for treating 277 indications other than cancer (Extended Data Fig. 3).

278

279 Evaluating associations of drugs approved for indications with cancer risk

We next evaluated the effect on cancer risk of therapeutic drugs that have been used long-term to treat indications based on real-world EHRs from the VUMC Synthetic Derivative (SD) database. Given a focal drug, we first emulated its trials by building control patient

groups who were exposed to similar treated drugs under the same ATC-L2 category (Online

284 Methods; Supplementary Table 13). To mimic randomized controlled trials (RCT) to 285 evaluate the focal drug's effect, we applied the Inverse Probability of Treatment Weighting (IPTW) framework⁶¹ to create a pseudo-population wherein confounding variables are evenly 286 287 distributed between the treated and control groups (Online Methods). After discarding the 288 trials with less than 500 eligible patients in either of the groups, we analyzed 14 treated 289 drugs with 335 balanced trials. Our analysis revealed that five drugs were linked to an 290 increased risk of cancer: Haloperidol (HR = 1.76; $P = 1.6 \times 10^{-23}$; targeting HLA-A protein) 291 and Trazodone (HR = 1.32; $P = 2.3 \times 10^{-12}$; targeting HLA-A protein) for breast cancer; 292 Tranexamic Acid (HR = 1.53; $P = 1.1 \times 10^{-3}$; targeting PLG protein) and Sirolimus (HR = 1.71; $P = 1.1 \times 10^{-28}$; targeting TYRO3 protein) for prostate cancer; and Haloperidol (HR = 293 294 2.62, $P = 6.6 \times 10^{-20}$, targeting HLA-A protein) and Captopril (HR = 1.65; $P = 2.2 \times 10^{-9}$; 295 targeting TF protein) for colorectal cancer (Fig. 6). In contrast, we also found that two drugs 296 associated with a decreased risk of colorectal cancer: Caffeine (HR = 0.74, P = 9.3×10^{-5} . targeting ALDH2 protein) and Acetazolamide (HR = 0.72: $P = 1.1 \times 10^{-20}$: targeting HLA-A 297

298 protein) (**Fig. 6**).

299

300 Discussion

301 In this study, we conducted a comprehensive investigation of cancer risk proteins by 302 integrating lead variants and pQTLs for six common cancer types using large-scale GWAS 303 and population-based proteomics data. Through pQTL mapping and subsequent 304 colocalization analysis, we identified 101 risk proteins across the six cancer types, with over 305 three-guarters of them not previously linked to cancer susceptibility. Moreover, most of the 306 proteins we identified are supported by functional genomics analyses. Our findings not only 307 significantly expand the pool of known cancer risk proteins but also offer new insights into 308 the biology and susceptibility of common cancers.

309

310 Through analysis of drug-protein interaction databases, we identified 36 druggable 311 proteins potentially targeted by 404 therapeutic drugs. Among these, 30 drugs have already 312 received approval for cancer treatment, while 73 are currently undergoing clinical trials for 313 cancer treatment. These findings offer genetic evidence supporting the effectiveness of 314 certain drugs and suggest potential opportunities for repurposing them to treat additional 315 cancers that share common risk proteins. However, it's crucial to acknowledge that while the 316 cancer risk proteins identified in our study hold promise as therapeutic targets for cancer 317 treatment, drugs may also have adverse effects, potentially exacerbating cancer 318 development through these targets (i.e., depending on their inhibitory or promotive effects)⁶².

Additionally, our analysis characterized 197 drugs used for indications other than cancer, which may influence cancer risk due to their interactions with cancer-risk proteins. Overall, our findings have the potential to accelerate therapeutic drug discovery for the prevention and intervention of human cancers.

323

324 We uncovered five non-cancer drugs associated with increased cancer risk: 325 Tranexamic Acid (PLG), Sirolimus (TYRO3), Haloperidol (HLA-A), Trazodone (HLA-A), and 326 Captopril (TF). Our genetic evidence or previous pharmacological studies further support 327 these findings. Specifically, Tranexamic Acid, an antifibrinolytic agent used to block the 328 breakdown of blood clots and prevent bleeding, was associated with an increased risk of 329 prostate cancer. Our findings suggest its potential inhibition of the protein expression of human plasminogen (PLG), based on data from the ChEMBL database. Our GWAS and 330 331 pQTL results indicate that PLG may serve as a potential tumor suppressor, supported by 332 evidence of the risk allele C of rs9347480 being associated with increased prostate cancer 333 risk ($P = 1.41 \times 10^{-07}$) and decreased protein expression ($P = 4.57 \times 10^{-33}$). Additionally, this protein also shows notable evidence of decreased gene expression (P = 0.038) in prostate 334 335 tumor samples compared to normal samples, as observed in data from TCGA. The drug 336 Sirolimus, primarily used to treat immune system and eye diseases, can potentially affect 337 receptor tyrosine kinases, TYRO3, a known protein important for prostate cancer 338 development^{63,64}. In breast and colorectal cancers, we identified two candidate drugs 339 (Haloperidol and Trazodone) targeting the major histocompatibility complex, HLA-A, an 340 essential protein for the immune system's defense against cancer development. 341 Interestingly, our analysis suggests that Haloperidol, a type of antipsychotic treatment, is 342 highly likely to increase the risk of both breast and colon cancer. Haloperidol, the first-343 generation antipsychotics, has been reported to be a carcinogenic compound⁶⁵ and its 344 exposure of five years or more was associated with an increased risk of breast cancer in a Finland nationwide study⁶². Consistently, another prior study showed its notably increased 345 346 risks of colorectal cancer in patients with schizophrenia who take antipsychotic 347 medications⁶⁶. We also found that Captopril, originally for cardiovascular diseases and promisingly repurposed for cancer treatment in clinical trials and several studies⁶⁷⁻⁷⁰, has the 348 349 potential to increase the risk of colorectal cancer, aligning with a previous study⁷¹. 350 351 Conversely, our study also identified two non-cancer drugs (Caffeine and 352 Acetazolamide) associated with a reduced risk of colorectal cancer. Acetazolamide,

353 prioritized by the risk protein named TF, exhibited a notable effect in preventing colorectal

354 cancer development (HR = 0.72, $P = 1.1 \times 10^{-20}$). In line with our findings, prior studies

demonstrated its role in inhibiting cell viability, migration, and colony formation ability of

colorectal cancer cells⁷², as well as its ability to suppress the development of intestinal
polyps in Min Mice⁷³. In addition, Caffeine, a drug prioritized by the risk protein ALDH2 in
colorectal cancer, has been shown to exert a protective effect on colorectal cancer by prior
studies^{74,75}. However, such low-risk association may vary by colon subsites⁷⁶ and specific
populations⁷⁷. Of note, a clinical trial (NCT05692024) is undergoing the recruitment phase to
evaluate the effects of instant coffee on the gut microbiome, metabolome, liver fat, and
fibrosis in colorectal cancer patients.

363

364 Although the larger sample size of the European-ancestry study available for both 365 GWAS and proteomics enabled us to identify a larger number of association signals for risk 366 protein discovery based on colocalization analysis, our study was primarily limited to 367 individuals of European ancestry and further investigations are needed to assess the 368 relevance of these proteins in non-European populations. Millions of EHRs provide an 369 unprecedented opportunity to systematically evaluate non-cancer drugs' effect on risk of 370 cancer development. Especially these therapeutic drugs have been used for a long time to 371 treat diseases other than cancers, which can provide appropriate statistical power for the 372 analysis. While this approach is limited in only examining the cancer risk of common 373 approved drugs, it serves as an efficient complementary method to the pre-clinical data 374 analysis for cancer prevention and treatment. Despite the supportive evidence of 375 Acetazolamide in vitro and in vivo, it remains necessary to evaluate the effects of our 376 reported candidate drugs through both in vitro and in vivo assays in future investigations. 377

378 Online Methods

379 Data resources

380 The GWAS summary statistics data of European descendants for breast, prostate, 381 ovarian, and lung cancers were downloaded and compiled from their corresponding consortia, including the Breast Cancer Association Consortium (BCAC)⁶ (N = 247,173, 382 383 133,384 cases and 113,789 controls), the Transdisciplinary Research of Cancer in Lung of 384 the International Lung Cancer Consortium (TRICL-ILCCO) and the Lung Cancer Cohort 385 Consortium $(LC3)^{13}$ (N = 85,716, 29,266 cases and 56,450 controls), the Ovary Cancer Association Consortium (OCAC)¹¹ (N = 63,347, 22,406 cases and 40,941 controls), and the 386 387 Pancreatic Cancer Case-Control Consortium (PanC4)¹⁰ (N = 21,536, 9,040 cases and 388 12,496 controls), and the Prostate Cancer Association Group Investigate Cancer Associated Alterations in the Genome (PRACTICAL)⁷⁸ (N = 140,306,79,194 cases and 61,112389 390 controls). For colorectal cancer, we included GWAS data of 125,487 subjects from the 391 European population.^{19,79,80} In addition, the GWAS data (N = 254,791) consisting of 100,204

392 colorectal cancer cases and 154,587 controls from European and Asian populations⁷ were 393 also used in our analysis.

394 The large-scale *cis*-protein quantitative trait loci (*cis*-pQTLs) among European-395 ancestry populations were analyzed based on three proteomics datasets: UKB-PPP³⁷ (N = 34,557, 2,922 plasma proteins), ARIC⁴⁴ (N = 7,213, 4,657 plasma proteins) and deCODE 396 397 genetics⁴⁵ (N = 35,559, 4,907 plasma proteins). Detailed descriptions of sample collection 398 and processes of the *cis*-pQTL analyses from the above proteomics datasets have been 399 described in previous studies^{37,46,47}.

400

401 We utilized the synthetic derivative (SD) database at Vanderbilt University Medical 402 Center (VUMC)⁸¹. This VUMC SD database contains de-identified clinical information 403 derived from Vanderbilt's electronic medical record The SD has longitudinal clinical data for 404 over 3.5 million individuals, including patient demographics, medical history, laboratory 405 results, and medication history.

406

407 Characterization of lead variants in six types of cancer

408 In breast cancer, we included 196 strong independent association signals at P < 1 x10⁻⁶ from a fine-mapping study⁵⁴ and 32 risk variants from a GWAS⁶. We first combined the 409 410 reported lead variants from these two studies after removing those variants in LD ($r^2 < 0.1$ in 411 European populations). We further included additional lead variants from SuSiE fine-412 mapping analysis on GWAS (N = 247,173)⁴⁸, with fine-mapping windows of 500 kilobases 413 (kb) and allowed a maximum of five causal variants. LD reference was based on the Britishancestry UK Biobank samples $(N = 337,000)^{82}$. We identified a credible set of causal 414 415 variants with a 95% posterior inclusion probability (95% PIP) for each independent risk 416 signal and a lead variant was represented by the variant with the minimum P. We included 417 additional lead variants from our SuSiE analysis with LD $r^2 < 0.1$ in European populations 418 with the above set of lead variants for those with independent risk-associated signals at GWAS $P < 5 \times 10^{-8}$ and located in GWAS loci with independent risk-associated signals at P 419 420 $< 1 \times 10^{-6}$ in European populations. 421

422 For colorectal cancer, we analyzed 238 lead variants from our recent fine-mapping 423 study⁵⁵ based on the GWAS data from 254,791 participants in both European and Asian 424 populations. We characterized 233 lead variants with independent risk-associated signals at 425 minimal $P < 1 \ge 10^{-6}$ in European populations, from the analysis based on GWAS from trans-426 ancestry and European populations, respectively. For prostate cancer, we first identified lead variants with independent risk-associated signals at GWAS $P < 5 \times 10^{-8}$ from our SuSiE fine-427

mapping analysis on GWAS summary statistics (N = 140,306). We next included additional

429 GWAS-identified risk variants with $P < 1 \times 10^{-6}$ in European populations from the previous trans-ancestry GWAS⁸ and $r^2 < 0.1$ with any lead variants from the above set in the fine-430 431 mapping analysis. Similarly, we used the above strategy to characterize lead variants from 432 fine-mapping analysis for ovarian cancer (N = 63,347) and pancreatic cancer (N = 21,536). 433 We next included additional risk variants that are missed in the above set of lead variants 434 from previous GWAS for ovarian¹¹ and pancreatic cancer¹⁰. For lung cancer, we included 26 435 risk variants at $P < 1 \ge 10^{-6}$ in European populations from the trans-ancestry GWAS⁹. 436 437 Identification of putative target proteins for lead variants

420 Tables if a state of the st

438 To identify potential cancer risk proteins, we mapped GWAS lead variants to cis-439 pQTLs (+/- 500Kb region of a gene) results from three studies among European populations: UK Biobank Pharma Proteomics Project³⁷, Atherosclerosis Risk in Communities study⁴⁴ and 440 deCODE genetics⁴⁵. To increase the power of pQTLs, we combined *cis*-pQTLs from the 441 442 ARIC and the deCODE (both assayed through SOMAscan® platform) via a a fixed-effects meta-analysis using META⁸³. *Cis*-pQTLs from the UKB-PPP (assayed through Olink 443 444 platform) were independently analyzed. In few cases where the lead variant did not overlap 445 with any *cis*-pQTLs, we substituted it with the correlated variant exhibiting the strongest 446 association signal. Putative cancer risk protein was defined based on pQTL significance at a 447 Bonferroni threshold of P < 0.05 (nominal $P = 2.3 \times 10^{-5}$, corresponding to 2,164 variant-448 protein tests for UKB-PPP; nominal $P = 3.8 \times 10^{-5}$, corresponding to 1,322 variant-protein 449 tests for ARIC+deCODE).

450

428

451 **Colocalization analyses between pQTL and GWAS signals**

To identify cancer risk proteins, we conducted colocalization analysis using two 452 approaches: Bayesian method *coloc*⁸⁴ and summary data-based Mendelian Randomization 453 454 (SMR)⁸⁵. For the SMR approach, a followed HEIDI test is performed on significant SMR 455 results to determine if the colocalized signals can be explained by one single causal variant or by multiple causal variants in the locus. For each protein, SNPs with P < 0.5 from GWAS. 456 457 MAF > 0.01, and within 50 kb of the lead variant were included. To estimate the posterior 458 probability (PP) of colocalization, we utilized the default priors and coloc.abf function. In our 459 study, we particularly focused on the assumption that one genetic variant is simultaneously 460 associated with both two traits, which was quantified by PP.H4. We considered a protein to 461 host one shared causal variant from GWAS and pQTLs if its *coloc* PP.H4 > 0.5. Additionally, 462 we also performed SMR+HEIDI analysis for significant *cis*-pQTL with default parameter 463 settings. Specifically, significant SMR+HEIDI results were defined as a tested locus with 464 Bonferroni-adjusted SMR P < 0.05 and HEIDI $P \ge 0.05$ (no obvious evidence of

heterogeneity of estimated effects or linkage). The above analyses were only conducted in
European populations available for both GWAS and proteomics in European populations.

468 **Functional genomic analyses**

For our identified cancer risk proteins, we examined their xQTLs, including eQTLs, sQTLs, and apaQTL using the resource from the GTEx (version 8). We collected eQTLs and sQTLs from six normal tissues and whole blood from GTEx studies, and we collected apaQTLs from Li's work⁸⁶. A nominal *P* value < 0.05 for at least one xQTL in either tissue or blood samples was considered supportive of the pQTL results.

474

475 We identified putative regulatory variants in strong linkage disequilibrium (LD) (r^2 > 476 0.8 in European population) for lead variants with significant colocalization between GWAS and *cis*-pQTL signals. Using the HaploReg tool⁸⁷, we annotated these variants with a variety 477 478 of epigenetic annotations, including regulatory chromatin states based on DNAse and 479 histone ChIP-Seq from Roadmap Epigenomics Project, histone marks for promoter and 480 enhancer, binding sites of transcription factors, and gene annotation from the GENCODE 481 and RefSeq. We denoted variants as "Proximal" if they overlapped with these functional 482 annotations near the closest target gene. We analyzed a variety of chromatin-chromatin interaction data, from 4D genome⁸⁸, FANTOM5⁸⁹, EnhancerAtlas⁹⁰, and super-enhancer⁹¹. 483 484 We examined the overlap between putative regulatory variants and enhancer elements in 485 corresponding cell lines or tissues of these six cancer types. We further determined 486 enhancer-promoter loops after combining these data with ChIP-seg data of the histone 487 modification H3K27ac (an active enhancer mark). We focused on interacted loops in which a 488 fragment overlapped an H3K27ac peak (enhancer-like elements). In contrast, the other 489 fragment overlapped the promoter of a gene (defined as a region of upstream 2kb and 490 downstream 100bp around transcript start site). We denoted variants as "Distal" if they 491 overlapped with these chromatin-chromatin variants.

492

For our identified cancer risk proteins, we assessed the statistical significance of their differential protein expression between tumor and normal tissue in breast, colorectal, lung, ovarian, and pancreatic cancer samples using data from CPTAC, accessed through the UALCAN website^{92,93}. Similarly, we analyzed their differential gene expression between tumor and normal tissue using data from TCGA, also through the UALCAN website.

499 Inclusion of patients for a focal drug and its control drugs

500 To evaluate the impact of a focal drug on cancer development, we conducted 501 comparisons between its effects and those of its control drugs. To minimize potential

502 confounding factors associated with a drug prescription, we selected control drugs that 503 belong to the same second-level Anatomical Therapeutic Chemical classification category 504 (ATC-L2) as the focal drug. We formulated emulation trials, each containing one treated 505 patient group (taking the focal drug) and one control patient group (taking the control drug). 506 One focal drug may have multiple trials, depending on the number of potential control drugs 507 belonging to the same ATC-L2 category. Next, we enrolled patients for the treated group and 508 the control group from the VUMC SD based on the following criteria: 1) patients aged \geq 40 at 509 the time of the latest EHRs or the initial diagnosis of cancer; 2) availability of at least one 510 year of EHRs before the first prescription of the treated/control drug (index date); 3) for 511 cancer patients, a minimum of two exposures to the treated or control drug during the follow-512 up period (from the index date to the three months before cancer diagnosis); 4) for noncancer individuals, a minimum of two exposures to control drugs during the follow-up period 513 514 (from the index date to the date of the latest EHRs). Finally, we precluded patients who were 515 prescribed both treated and control drugs and discarded the trials with less than 500 eligible 516 patients in either patient group⁴⁰.

517

518 Emulation of treated-control drugs balanced trials

519 In the IPTW framework⁶¹, individuals are assigned weights based on the inverse of 520 their propensity scores (PS), which represent their probability of being exposed to risk 521 factors or a specific intervention, such as a treated drug, based on their baseline 522 characteristics. In this study, we followed Zang's work⁴⁰ and trained a logistic regression 523 propensity score (LR-PS) model with L1 or L2 regularization on patients' treatment 524 assignments Z and covariates, including age, gender, comorbidities, etc. (Supplementary 525 Table 14). We trained and selected the logistic model (Eq.1) with the highest area under 526 curve (AUC) using a 10-folder cross-validation. We used the selected model to calculate all 527 patient's stabilized weights (Eq. 2). These weights are used to calculate the standardized 528 mean difference (SMD, Eq.3) of the covariate's prevalence in treated and control groups. A 529 covariate d is defined as unbalanced if SMD(d) > 0.1 in IPTW framework (Eqs. 3, 4). A trial 530 is balanced if it contains $\leq 10\%$ unbalanced covariates (Eq. 5).

531

532 The logistic regression is defined as follows:

$$\log\left(\frac{P(\mathbf{Z}=1)}{1-P(\mathbf{Z}=1)}\right) = \beta_0 + \beta_1 X_1 + \beta_2 X_2 + \dots + \beta_n X_n$$

$$P(\mathbf{Z}=1) = \frac{1}{1+e^{-(\sum \beta_j X_j + \beta_0)}}$$
1

- 533 where Z refers to treatment assignment (1 for treated patient group and 0 for control patient
- group) and $X(X_1, X_2, ..., X_n)$ for baseline covariates. The propensity score is defined as
- 535 $P(\mathbf{Z} = 1 | \mathbf{X})$ and the stabilized IPTW of each individual is calculated as follows:

$$\mathbf{w} = \frac{\mathbf{Z} \times P(\mathbf{Z} = 1)}{P(\mathbf{Z} = 1 | \mathbf{X})} + \frac{(1 - \mathbf{Z}) \times (1 - P(\mathbf{Z} = 1))}{1 - P(\mathbf{Z} = 1 | \mathbf{X})}$$
2

536

537 Standardized mean difference is calculated as following:

$$SMD(\boldsymbol{x}_{treat} - \boldsymbol{x}_{control}) = \frac{|\boldsymbol{\mu}_{treat} - \boldsymbol{\mu}_{control}|}{\sqrt{(\boldsymbol{S}_{treat}^2 + \boldsymbol{S}_{control}^2)/2}}$$
3

538 $x_{treat}, x_{control} \in \mathbb{R}^{D}$, representing vectors of D number of covariates of treated group and

539 control group respectively; μ_{treat} , $\mu_{control}$ are their sample means, and S_{treat}^2 , $S_{control}^2$ are

540 their sample variances. In IPTW framework, the weighted sample mean μ_w and sample

541 variance S_w^2 are calculated as following:

$$\mu_{w} = \frac{\sum w_{i} x_{i}}{\sum w_{i}}$$

$$= \frac{\sum w_{i}}{(\sum w_{i})^{2} - \sum w_{i}^{2}} \sum w_{i} (x_{i} - \mu_{w})^{2}$$

$$4$$

542

543 Number of unbalanced covariates are calculated as following:

 S_w^2

$$n = \sum_{d=1}^{D} \mathbb{1}[SMD(d) > 0.1]$$

5

544

where D is the total number of covariates in the model, d is one covariate

545

546 Logistic regression propensity score (LR-PS) hyperparameter selection and model 547 training

To select the optimal regulation penalty weight (λ), we applied 10-fold cross-548 549 validation on a list of lambda elements $\lambda \in [0.005, 0.01, 0.05, 0.1, 0.5]$. Specifically, the 550 logistic model was trained on 9 training folders, and learnable parameters (β) were 551 estimated through minimizing the binary cross-entropy loss with L1 (Eq. 6) or L2 penalty (Eq. 552 7). On the left-one out validation folder (k), we calculated SMD_k (Eq. 3) values for 553 D covariates based on individuals' weights (Eq. 2) as well as the number unbalanced 554 covariates n_k (Eq. 5). In addition, we evaluated trained model's prediction performance 555 using area under curve (AUC_k) on the validation dataset. The same processes were 556 repeated 10 times. We defined the optimal hyperparameter value is the value generates the smallest averaged n_k . For two hyperparameter values generate approximate n_k , the one 557 558 with larger averaged AUC_k is the optimal. Finally, we trained LR-PS model's learnable

- parameters (β) on all subjects with the optimal hyperparameter and leveraged this trained
- 560 model to compute weights and the proportion of imbalanced covariates to pinpoint balanced

trials.

- 562
- 563 Binary cross-entropy loss function with LASSO (L1) penalization:

$$argmin_{\beta}(Loss) = -\frac{1}{n} \left(\sum_{i=1}^{n} z_i \log(P(z_i = 1)) + (1 - z_i) \log(1 - P(z_i = 1)) \right) + \lambda_1 \sum_{j=1}^{b} |\beta_j|$$
⁶

564 Binary cross-entropy loss function with ridge (L2) penalization:

$$argmin_{\beta}(Loss) = -\frac{1}{n} \left(\sum_{i=1}^{n} z_i \log(P(z_i = 1)) + (1 - z_i) \log(1 - P(z_i = 1)) \right) + \lambda_2 \sum_{j=1}^{b} \beta_j^2$$
⁷

565 **Calculation of overall hazard ratio for cancer risk drug on cancer development risk**

We evaluate subjects' hazard of developing/preventing cancer in balanced treated-566 567 control trials through survival analyses. We applied weighted Cox proportional hazard 568 model⁹⁴ using the lifelines 0.28.0 Python package to systematically evaluate the hazard ratio 569 of developing cancer for patients taking treated drug vs patients taking control drugs (time-570 to-event). The time windows utilized in this study start from the earliest date in EHRs for 571 prescription of the treated/control drug to patients and end at the date of the diagnosis of 572 cancer (event) or the end of EHRs records (censored). We included unbalanced covariates 573 (if exist) into Cox models. For a treated drug, its overall hazard ratio and p-value were 574 obtained by applying a random effect meta-analysis on the hazard ratios from its eligible 575 trials using the meta 7.0 R package (Supplementary Table 15). We reported that a treated 576 drug has a significantly increasing or decreasing risk of cancer development, contrasting to 577 its control drugs, if the overall hazard ratio has a P < 0.05 after Bonferroni correction

- 578 (nominal $P = 3.5 \times 10^{-3}$ corresponding to 14 tests).
- 579

580 Data availability

581 Supplementary Table 1 provides the download information for the summary statistics of

- 582 GWAS data for the six common cancers, including breast, ovary, prostate, colorectum, lung,
- and pancreas. Metadata and pQTL summary statistics from UKB-PPP can be downloaded
- 584 from Synapse: Project SynID: syn51364943; pQTL from ARIC⁴⁶ and deCODE genetics⁴⁷ can
- 585 be accessed through previous publications (PMID: 34857953 and PMID: 35501419).
- 586 Functional genomic data includes: TCGA and CPTAC differential expression results
- 587 accessible through <u>https://ualcan.path.uab.edu/index.html;</u> 4DGenome:
- 588 <u>https://4dgenome.research.chop.edu/;</u> Depmap : <u>https://depmap.org/portal/;</u> FANTOM5:
- 589 <u>http://fantom.gsc.riken.jp/5/</u>. HaploReg: <u>https://pubs.broadinstitute.org/mammals/haploreg/</u>.

- 590 GTEx: https://gtexportal.org/home/. GENCODE (v26.GRCh38) was downloaded from
- 591 <u>https://www.gencodegenes.org/human/release_26.html</u>. National Cancer Institute can be
- 592 accessed through <u>https://www.cancer.gov/about-cancer/treatment/drugs;</u> CGC can be
- 593 accessed via COSMIC website: https://cancer.sanger.ac.uk/census. Drugs and
- 594 compounds data can be downloaded from the following URLs: ChEMBL:
- 595 <u>https://www.ebi.ac.uk/chembl/;</u> Therapeutic Target Database: <u>https://db.idrblab.net/ttd/;</u>
- 596 Open Targets: https://www.opentargets.org/; DrugBank: https://go.drugbank.com/. The EHR
- 597 data, containing de-identified clinical information, can be accessed through the VUMC SD
- 598 database. Data is available through restricted access for approved studies and researchers
- 599 who agree to specific conditions of use.
- 600

601 Code availability

- 602 The developed pipeline and main source R codes that are used in this work are available
- 603 from the GitHub website of Xingyi Guo's lab: <u>https://github.com/XingyiGuo/PQTL_EHR/</u>

604 **Declaration of Interests**

- 605 The authors declare no competing interests.
- 606

607 Acknowledgments

- 608 This work was supported by the US National Institutes of Health grant 1R37CA227130-01A1
- and R01CA269589-01A1 to X.G. The data analyses were conducted using the Advanced
- 610 Computing Center for Research and Education (ACCRE) at Vanderbilt University. New
- 611 Frontiers in Research Fund (NFRFE-2018-00748) and NSERC Discovery Grant (RGPIN-
- 612 2024-04679) to Q.L. The computational infrastructure was partly supported by a Canada
- 613 Foundation for Innovation JELF grant (36605) to Q.L.

614 **References**

 Nature genetics 47, Sbb-B0 (2015). Diogo, D., <i>et al.</i> Phenome-wide association studies across large population cohorts support drug target validation. <i>Nature communications</i> 9, 4285 (2018). Finan, C., <i>et al.</i> The druggable genome and support for target identification and validation in drug development. <i>Sci Transi Med</i> 9(2017). Peters, U. & Tomlisson, I. Utilizing Human Genetics to Develop Chemoprevention for Cancer-Too Good an Opportunity to be Missed. <i>Cancer Prev Res (Philo</i>) 17, 7-12 (2024). Jia, G., <i>et al.</i> Genome- and transcriptome-wide association studies of 386,000 Asian and European-ancestry women provide new insights into breast cancer genetics. <i>Am J Hum Genet</i> 109, 2185-2195 (2022). Zhang, H., <i>et al.</i> Genome-wide association study identifies 22 novel breast cancer susceptibility loci from overall and subtype-specific analyses. <i>Nature genetics</i> 52, 572-581 (2020). Fernandez-Rozadilla, C., <i>et al.</i> Deciphering colorectal cancer genetics. <i>Hum Uni-omic analysis</i> of 100,204 cases and 154,587 controls of European and east Asian ancestries. <i>Nat Genet</i> 55, 89-99 (2023). Controls Jouz, <i>et al.</i> Cross-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction. <i>Nature genetics</i> 53, 65-75 (2021). Byun, J., <i>et al.</i> Cross-ancestry genome-wide meta-analysis of 61,047 cases and 947,237 controls identifies new susceptibility loci contributing to lung cancer. <i>Nature genetics</i> 54, 1167-1177 (2022). Klein, A.P., <i>et al.</i> Genome-wide meta-analysis identifies five new susceptibility loci for pancreatic cancer. <i>Nature genetics</i> 49, 680-691 (2017). Lawrenson, K., <i>et al.</i> Genome-wide association studies identify susceptibility loci for epithelial ovarian cancer in east Asian women. Gynecol Oncol 153, 343-355 (2019). McKay, J.D., <i>et al.</i> Large-scale association analysis identifies	615	1.	Nelson, M.R., <i>et al.</i> The support of human genetic evidence for approved drug indications.
 Diogo, D., <i>et al.</i> Phenome-wide association studies across large population cohorts support drug target validation. <i>Nature communications</i> 9, 4285 (2018). Finan, C., <i>et al.</i> The druggable genome and support for target identification and validation in drug development. <i>Sci Transl Med</i> 9(2017). Peters, U. & Tomlinson, I. Utilizing Human Genetics to Develop Chemoprevention for Cancer-Too Good an Opportunity to be Missed. <i>Cancer Prev Res (Philo)</i> 17, 7-12 (2024). Jia, G., <i>et al.</i> Genome- and transcriptome-wide association studies of 386,000 Asian and European-ancestry women provide new insights into breast cancer genetics. <i>Am J Hum Genet</i> 109, 2185-2195 (2022). Zhang, H., <i>et al.</i> Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses. <i>Nature genetics</i> 52, 572-581 (2020). Fernandez-Rozadilla, C., <i>et al.</i> Deciphering colorectal cancer genetics through multi-omic analysis of 100,204 cases and 154,587 controls of European and east Asian ancestries. <i>Nat Genet</i> 55, 89-99 (2023). Conti, D.V., <i>et al.</i> Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction. <i>Nature genetics</i> 53, 65-75 (2021). Byun, J., <i>et al.</i> Cross-ancestry genome-wide meta-analysis of 61,047 cases and 947,237 controls identifies new susceptibility loci for gancreatic cancer. <i>Nature genetics</i> 54, 107-1177 (2022). Klein, A.P., <i>et al.</i> Genome-wide association studies identify susceptibility loci for pancreatic cancer. <i>Nature genetics</i> 49, 680-691 (2017). Lawrenson, K., <i>et al.</i> Genome-wide association analysis identifies five new susceptibility loci for epithelial ovarian cancer. <i>Nature genetics</i> 49, 680-691 (2017). Klein, A.P., <i>et al.</i> Genome-wide association studies identify susceptibility loci for epithelial ovarian cancer. <i>Nature genetics</i>	616	-	Nature genetics 47, 856-860 (2015).
 Finan, C., <i>et al.</i> The druggable genome and support for target identification and validation in drug development. <i>Sci Transl Med</i> 9(2017). Peters, U. & Tomlinson, I. Utilizing Human Genetics to Develop Chemoprevention for Cancer-Too Good an Opportunity to be Missed. <i>Cancer Prev Res (Phila)</i> 17, 7-12 (2024). Jia, G., <i>et al.</i> Genome- and transcriptome-wide association studies of 386,000 Asian and European-ancestry women provide new insights into breast cancer genetics. <i>Am J Hum Genet</i> 109, 2185-2195 (2022). Zhang, H., <i>et al.</i> Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses. <i>Nature genetics</i> 52, 572-581 (2020). Fernandez-Rozadilla, C., <i>et al.</i> Deciphering colorectal cancer genetics through multi-omic analysis of 100,204 cases and 154,587 controls of European and east Asian ancestries. <i>Nat Genet</i> 55, 89-99 (2023). Conti, D.V., <i>et al.</i> Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction. <i>Nature genetics</i> 53, 65-75 (2021). Byun, J., <i>et al.</i> Cross-ancestry genome-wide meta-analysis of 61,047 cases and 947,237 controls identifies new susceptibility loci contributing to lung cancer. <i>Nature genetics</i> 54, 1167-1177 (2022). Klein, A.P., <i>et al.</i> Genome-wide meta-analysis identifies five new susceptibility loci for pancreatic cancer. <i>Nature genetics</i> 54, 1167-1177 (2022). Klein, A.P., <i>et al.</i> Genome-wide association studies identify susceptibility loci for epithelial ovarian cancer. <i>Nature</i> 69, 680-691 (2017). Kelan, C.M., <i>et al.</i> Genome-wide association studies identify susceptibility loci for epithelial ovarian cancer in east Asian women. <i>Gynecol Oncol</i> 153, 343-355 (2016). Metay, J.D., <i>et al.</i> Genome-wide association studies identify susceptibility loci for epithelial ovarian c	617 618	2.	Diogo, D., et al. Phenome-wide association studies across large population cohorts support drug target validation. <i>Nature communications</i> 9 , 4285 (2018).
 drug development. <i>Sci Trans Med</i> 9(2017). Peters, U. & Tomlinson, I. Utilizing Human Genetics to Develop Chemoprevention for Cancer-Too Good an Opportunity to be Missed. <i>Cancer Prev Res</i> (Philo) 17, 7-12 (2024). Jia, G., <i>et al.</i> Genome- and transcriptome-wide association studies of 386,000 Asian and European-ancestry women provide new insights into breast cancer genetics. <i>Am J Hum Genet</i> 109, 2185-2195 (2021). Zhang, H., <i>et al.</i> Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses. <i>Nature genetics</i> 52, 572-581 (2020). Fernandez-Rozadilla, C., <i>et al.</i> Deciphering colorectal cancer genetics through multi-omic analysis of 100,204 cases and 154,587 controls of European and east Asian ancestries. <i>Nat Genet</i> 55, 59-99 (2023). Conti, D. V., <i>et al.</i> Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction. <i>Nature genetics</i> 53, 65-75 (2011). Byun, J., <i>et al.</i> Cross-ancestry genome-wide meta-analysis of 10,047 cases and 947,237 controls follitily loci and informs genetic risk prediction. <i>Nature genetics</i> 54, 1167-1177 (2022). Klein, A.P., <i>et al.</i> Genome-wide meta-analysis identifies five new susceptibility loci for epithelial ovarian cancer. <i>Nature genetics</i> 49, 680-691 (2017). Lawrenson, K., <i>et al.</i> Genome-wide association studies identifiy susceptibility loci for epithelial ovarian cancer in east Asian women. <i>Gynecol I</i> 153, 343-355 (2019). McKay, J.D., <i>et al.</i> Large-scale association studies identify susceptibility loci for epithelial ovarian cancer in east Asian women. <i>Gynecol Oncol</i> 153, 343-355 (2019). McKay, J.D., <i>et al.</i> Colon-specific eQTL analysis to inform on functional SNPs. <i>Br J Cancer</i> 119, 971-977 (2018). Chen, Z., <i>et al.</i> Genetic variations of DNA bindings of FOXA1 and co-fa	619	З	Finan C et al. The druggable genome and support for target identification and validation in
 Peters, U. & Tomlinson, I. Utilizing Human Genetics to Develop Chemoprevention for Cancer- Too Good an Opportunity to be Missed. <i>Cancer Prev Res (Phila)</i> 17, 7-12 (2024). Jia, G., <i>et al.</i> Genome- and transcriptome-wide association studies of 386,000 Asian and European-ancestry women provide new insights into breast cancer genetics. <i>Am J Hum Genet</i> 109, 2185-2195 (2022). Zhang, H., <i>et al.</i> Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses. <i>Nature genetics</i> 52, 572-581 (2020). Fernandez-Rozadilla, C., <i>et al.</i> Deciphering colorectal cancer genetics through multi-omic analysis of 100,204 cases and 154,587 controls of European and east Asian ancestries. <i>Nat Genet</i> 55, 89-99 (2023). Conti, D.V., <i>et al.</i> Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction. <i>Nature genetics</i> 53, 65- 75 (2021). Byun, J., <i>et al.</i> Cross-ancestry genome-wide meta-analysis of 61,047 cases and 947,237 controls identifies new susceptibility loci contributing to lung cancer. <i>Nature genetics</i> 54, 1167-1177 (2022). Klein, A.P., <i>et al.</i> Genome-wide meta-analysis identifies five new susceptibility loci for pancreatic cancer. <i>Nat Commun</i> 9, 556 (2018). Phelan, C.M., <i>et al.</i> Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. <i>Nature genetics</i> 49, 680-691 (2017). Lawrenson, K., <i>et al.</i> Genome-wide association studies identifies new lung cancer susceptibility loci and heterogeneity in genetic susceptibility across histological subtypes. <i>Nature genetics</i> 49, 1126-1132 (2017). Wen, W., <i>et al.</i> Genome-wide association studies identifies new lung cancer susceptibility loci and heterogeneity in genetic susceptibility across histological subtypes. <i>Nature genetics</i> 49, 1126-1132 (2	620	э.	drug development. Sci Transl Med 9(2017).
 Too Good an Opportunity to be Missed. <i>Cancer Prev Res (Phila)</i> 17, 7-12 (2024). 5. Jia, G., <i>et al.</i> Genome- and transcriptome-wide association studies of 386,000 Asian and European-ancestry women provide new insights into breast cancer genetics. <i>Am J Hum Genet</i> 109, 2185-2195 (2022). 6. Zhang, H., <i>et al.</i> Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses. <i>Nature genetics</i> 52, 572-581 (2020). 7. Fernandez-Rozadilla, C., <i>et al.</i> Deciphering colorectal cancer genetics through multi-omic analysis of 100,204 cases and 154,587 controls of European and east Asian ancestries. <i>Nat Genet</i> 55, 89-99 (2023). 8. Conti, D.V., <i>et al.</i> Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction. <i>Nature genetics</i> 53, 65-75 (2021). 9. Byun, J., <i>et al.</i> Cross-ancestry genome-wide meta-analysis of 61,047 cases and 947,237 controls identifies new susceptibility loci contributing to lung cancer. <i>Nature genetics</i> 54, 1167-1177 (2022). 10. Klein, A.P., <i>et al.</i> Genome-wide meta-analysis identifies new susceptibility loci for gpancreatic cancer. <i>Nat genetics</i> 49, 680-691 (2017). 11. Phelan, C.M., <i>et al.</i> Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. <i>Nature genetics</i> 49, 680-691 (2017). 12. Lawrenson, K., <i>et al.</i> Genome-wide association studies identify susceptibility loci for epithelial ovarian cancer in east Asian women. <i>Gynecol Oncol</i> 153, 343-355 (2019). 13. McKay, J.D., <i>et al.</i> Large-scale association analysis identifies new lung cancer susceptibility loci and heterogeneity in genetic susceptibility across histological subtypes. <i>Nature genetics</i> 49, 9126-1132 (2017). 14. Wen, W., <i>et al.</i> Genome-wide susceptibility Gen	621	4	Peters, U. & Tomlinson, I. Utilizing Human Genetics to Develop Chemoprevention for Cancer-
 Jia, G., <i>et al.</i> Genome- and transcriptome-wide association studies of 386,000 Asian and European-ancestry women provide new insights into breast cancer genetics. <i>Am J Hum</i> <i>Genet</i> 109, 2185-2195 (2022). Zhang, H., <i>et al.</i> Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses. <i>Nature genetics</i> 52, 572-581 (2020). Fernandez-Rozadilla, C., <i>et al.</i> Deciphering colorectal cancer genetics through multi-omic analysis of 100,204 cases and 154,587 controls of European and east Asian ancestries. <i>Nat Genet</i> 55, 89-99 (2023). Conti, D.V., <i>et al.</i> Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction. <i>Nature genetics</i> 53, 65- 75 (2021). Byun, J., <i>et al.</i> Cross-ancestry genome-wide meta-analysis of 61,047 cases and 947,237 controls identifies new susceptibility loci contributing to lung cancer. <i>Nature genetics</i> 54, 1167-1177 (2022). Klein, A.P., <i>et al.</i> Genome-wide meta-analysis identifies five new susceptibility loci for pancreatic cancer. <i>Nat Commun</i> 9, 556 (2018). Phelan, C.M., <i>et al.</i> Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer in east Asian women. <i>Gynecol Oncol</i> 153, 343-355 (2019). McKay, J.D., <i>et al.</i> Large-scale association analysis identifies new lung cancer susceptibility loci and heterogeneity in genetic susceptibility and co-factors in breast cancer susceptibility. <i>Nature communications</i> 12, 5318 (2021). Worn, W., <i>et al.</i> Compene-wide Association form on functional SNPs. <i>Br J Cancer</i> 119, 971-977 (2018). Moreno, V., <i>et al.</i> Acomprehensive cis-eQTL Analysis Revealed Target Genes in Breast Cancer susceptibility. <i>Nature communications</i> 12, 5318 (2021). He, J., <i>et al.</i> Acomprehensive cis-eQTL Analysis Revealed Target Genes in Breast Cancer su	622		Too Good an Opportunity to be Missed. <i>Cancer Prev Res (Phila)</i> 17 , 7-12 (2024).
 European-ancestry women provide new insights into breast cancer genetics. <i>Am J Hum</i> <i>Genet</i> 109, 2185-2195 (2022). Zhang, H., <i>et al.</i> Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses. <i>Nature genetics</i> 52, 572-581 (2020). Fernandez-Rozadilla, C., <i>et al.</i> Deciphering colorectal cancer genetics through multi-omic analysis of 100,204 cases and 154,587 controls of European and east Asian ancestries. <i>Nat Genet</i> 55, 89-99 (2023). Conti, D.V., <i>et al.</i> Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction. <i>Nature genetics</i> 53, 65- 75 (2021). Byun, J., <i>et al.</i> Cross-ancestry genome-wide meta-analysis of 61,047 cases and 947,237 controls identifies new susceptibility loci contributing to lung cancer. <i>Nature genetics</i> 54, 1167-1177 (2022). Klein, A.P., <i>et al.</i> Genome-wide meta-analysis identifies five new susceptibility loci for pancreatic cancer. <i>Nat Commun</i> 9, 556 (2018). Phelan, C.M., <i>et al.</i> Genome-wide association studies identify susceptibility loci for epithelial ovarian cancer. <i>Nature genetics</i> 49, 680-691 (2017). Lawrenson, K., <i>et al.</i> Genome-wide association studies identify susceptibility loci for epithelial ovarian cancer in east Asian women. <i>Gynecol Oncol</i> 153, 343-355 (2019). McKay, J.D., <i>et al.</i> Large-scale association analysis identifies new lung cancer susceptibility loci and heterogeneity in genetic susceptibility across histological subtypes. <i>Nature genetics</i> 49, 1126-1132 (2017). Wen, W., <i>et al.</i> Genetic variations of DNA bindings of FOXA1 and co-factors in breast cancer susceptibility. <i>Nature communications</i> 12, 5318 (2021). Moreno, V., <i>et al.</i> Icolon-specific eQTL analysis to inform on functional SNPs. <i>Br J Cancer</i> 119, 971-977 (2018). Chen, Z., <i>et al.</i> Identifyi	623	5.	Jia, G., et al. Genome- and transcriptome-wide association studies of 386,000 Asian and
 <i>Genet</i> 109, 2185-2195 (2022). <i>Chang, H., et al.</i> Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses. <i>Nature genetics</i> 52, 572-581 (2020). <i>Fernandez-Rozadilla, C., et al.</i> Deciphering colorectal cancer genetics through multi-omic analysis of 100,204 cases and 154,587 controls of European and east Asian ancestries. <i>Nat Genet</i> 55, 89-99 (2023). Conti, D.V., <i>et al.</i> Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction. <i>Nature genetics</i> 53, 65-75 (2021). Byun, J., <i>et al.</i> Cross-ancestry genome-wide meta-analysis of 61,047 cases and 947,237 controls identifies new susceptibility loci contributing to lung cancer. <i>Nature genetics</i> 54, 1167-1177 (2022). Klein, A.P., <i>et al.</i> Genome-wide meta-analysis identifies five new susceptibility loci for pancreatic cancer. <i>Nature genetics</i> 49, 580-691 (2017). Phelan, C.M., <i>et al.</i> Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. <i>Nature genetics</i> 49, 680-691 (2017). Lawrenson, K., <i>et al.</i> Genome-wide association analysis identifies new lung cancer susceptibility loci and heterogeneity in genetic susceptibility action files new lung cancer susceptibility loci and heterogeneity in genetic susceptibility actions histological subtypes. <i>Nature genetics</i> 49, 1126-1132 (2017). Wen, W., <i>et al.</i> Celon-specific eQTL analysis to inform on functional SNPs. <i>Br J Cancer</i> 119, 971-977 (2018). Moreno, V., <i>et al.</i> Identifying Putative Susceptibility Genes and Evaluating Their Association with Somatic Mutations in Human Cancers. <i>American journal of human genetics</i> 105, 477-492 (2019). Moreno, V., <i>et al.</i> Identifying Putative Susceptibility Genes and Evaluating Their Association swith Somatic Mutations in Human Cancers. <i>America</i>	624		European-ancestry women provide new insights into breast cancer genetics. Am J Hum
 Chang, H., <i>et al.</i> Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses. <i>Nature genetics</i> 52, 572-581 (2020). Fernandez-Rozadilla, C., <i>et al.</i> Deciphering colorectal cancer genetics through multi-omic analysis of 100, 204 cases and 154,587 controls of European and east Asian ancestries. <i>Nat Genet</i> 55, 89-99 (2023). Conti, D.V., <i>et al.</i> Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction. <i>Nature genetics</i> 53, 65- 75 (2021). Byun, J., <i>et al.</i> Cross-ancestry genome-wide meta-analysis of 61,047 cases and 947,237 controls identifies new susceptibility loci contributing to lung cancer. <i>Nature genetics</i> 54, 1167-1177 (2022). Klein, A.P., <i>et al.</i> Genome-wide meta-analysis identifies five new susceptibility loci for pancreatic cancer. <i>Natu Commun</i> 9, 556 (2018). Klein, A.P., <i>et al.</i> Genome-wide association studies identify susceptibility loci for epithelial ovarian cancer. <i>Nature genetics</i> 49, 680-691 (2017). Lawrenson, K., <i>et al.</i> Genome-wide association studies identify susceptibility loci for epithelial ovarian cancer in east Asian women. <i>Gynecol Oncol</i> 153, 343-355 (2019). McKay, J.D., <i>et al.</i> Large-scale association analysis identifies new lung cancer susceptibility loci and heterogeneity in genetic susceptibility across histological subtypes. <i>Nature genetics</i> 49, 1126-1132 (2017). Moreno, V., <i>et al.</i> Colon-specific eQTL analysis to inform on functional SNPs. <i>Br J Cancer</i> 119, 971-977 (2018). Chen, Z., <i>et al.</i> Ale Genetic variations of DNA bindings of FOXA1 and co-factors in breast cancer susceptibility. <i>Nature communications</i> 12, 5318 (2021). Moreno, V., <i>et al.</i> Comprehensive cis-eQTL Analysis Revealed Target Genes in Breast Cancer Susceptibility Loci Identifying Putative Susceptibility Gene	625		Genet 109 , 2185-2195 (2022).
 susceptibility loci from overall and subtype-specific analyses. <i>Nature genetics</i> 52, 572-581 (2020). Fernandez-Rozadilla, C., <i>et al.</i> Deciphering colorectal cancer genetics through multi-omic analysis of 100,204 cases and 154,587 controls of European and east Asian ancestries. <i>Nat Genet</i> 55, 89-99 (2023). Conti, D.V., <i>et al.</i> Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction. <i>Nature genetics</i> 53, 65-75 (2021). Byun, J., <i>et al.</i> Cross-ancestry genome-wide meta-analysis of 61,047 cases and 947,237 controls identifies new susceptibility loci contributing to lung cancer. <i>Nature genetics</i> 54, 1167-1177 (2022). Klein, A.P., <i>et al.</i> Genome-wide meta-analysis identifies five new susceptibility loci for pancreatic cancer. <i>Nat Commun</i> 9, 556 (2018). Klein, A.P., <i>et al.</i> Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. <i>Nature genetics</i> 49, 680-691 (2017). Lawrenson, K., <i>et al.</i> Genome-wide association studies identify susceptibility loci for epithelial ovarian cancer in east Asian women. <i>Gynecol Oncol</i> 153, 343-355 (2019). McKay, J.D., <i>et al.</i> Large-scale association analysis identifies new lung cancer susceptibility loci and heterogeneity in genetic susceptibility across histological subtypes. <i>Nature genetics</i> 49, 1126-1132 (2017). Wen, W., <i>et al.</i> Genotic variations of DNA bindings of FOXA1 and co-factors in breast cancer susceptibility. <i>Nature communications</i> 12, 5318 (2021). Moreno, V., <i>et al.</i> Colon-specific eQTL analysis to inform on functional SNPs. <i>Br J Cancer</i> 119, 971-977 (2018). Chen, Z., <i>et al.</i> Acomprehensive cis-eQTL Analysis Revealed Target Genes in Breast Cancer Susceptibility loci dentifies susceptibility Genes for Colorectal Cancer susceation analysis identifies susceptibility Loci dentifies susceptibil	626	6.	Zhang, H., et al. Genome-wide association study identifies 32 novel breast cancer
 (2020). Fernandez-Rozadilla, C., <i>et al.</i> Deciphering colorectal cancer genetics through multi-omic analysis of 100,204 cases and 154,587 controls of European and east Asian ancestries. <i>Nat</i> <i>Genet</i> 55, 89-99 (2023). Conti, D.V., <i>et al.</i> Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction. <i>Nature genetics</i> 53, 65- 75 (2021). Byun, J., <i>et al.</i> Cross-ancestry genome-wide meta-analysis of 61,047 cases and 947,237 controls identifies new susceptibility loci contributing to lung cancer. <i>Nature genetics</i> 54, 1167-1177 (2022). Klein, A.P., <i>et al.</i> Genome-wide meta-analysis identifies five new susceptibility loci for pancreatic cancer. <i>Nat Commun</i> 9, 556 (2018). Klein, A.P., <i>et al.</i> Genome-wide association studies identify susceptibility loci for epithelial ovarian cancer. <i>Nature genetics</i> 49, 680-691 (2017). Lawrenson, K., <i>et al.</i> Genome-wide association studies identify susceptibility loci for epithelial ovarian cancer in east Asian women. <i>Gynecol Oncol</i> 153, 343-355 (2019). McKay, J.D., <i>et al.</i> Large-scale association analysis identifies new lung cancer susceptibility loci and heterogeneity in genetic susceptibility across histological subtypes. <i>Nature genetics</i> 49, 1126-1132 (2017). Wen, W., <i>et al.</i> Genome-wide Susceptibility Genes and Evaluating Their Associations with Somatic Mutations in Human Cancers. <i>American journal of human genetics</i> 105, 477- 492 (2019). Moreno, V., <i>et al.</i> Colon-specific eQTL analysis to inform on functional SNPs. <i>Br J Cancer</i> 119, 971-977 (2018). Chen, Z., <i>et al.</i> Identifying Putative Susceptibility Genes and Evaluating Their Associations with Somatic Mutations in Human Cancers. <i>American journal of human genetics</i> 105, 477- 492 (2019). He, J., <i>et al.</i> Integrating transcription factor occupancy with transcriptome-wide associati	627		susceptibility loci from overall and subtype-specific analyses. Nature genetics 52, 572-581
 Fernandez-Rozadilla, C., <i>et al.</i> Deciphering colorectal cancer genetics through multi-omic analysis of 100,204 cases and 154,587 controls of European and east Asian ancestries. <i>Nat</i> <i>Genet</i> 55, 89-99 (2023). Conti, D.V., <i>et al.</i> Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction. <i>Nature genetics</i> 53, 65- 75 (2021). Byun, J., <i>et al.</i> Cross-ancestry genome-wide meta-analysis of 61,047 cases and 947,237 controls identifies new susceptibility loci contributing to lung cancer. <i>Nature genetics</i> 54, 1167-1177 (2022). Klein, A.P., <i>et al.</i> Genome-wide meta-analysis identifies five new susceptibility loci for pancreatic cancer. <i>Nat Commun</i> 9, 556 (2018). Phelan, C.M., <i>et al.</i> Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. <i>Nature genetics</i> 49, 680-691 (2017). Lawrenson, K., <i>et al.</i> Genome-wide association studies identify susceptibility loci for epithelial ovarian cancer in east Asian women. <i>Gynecol Oncol</i> 153, 343-355 (2019). McKay, J.D., <i>et al.</i> Large-scale association analysis identifies new lung cancer susceptibility loci and heterogeneity in genetic susceptibility across histological subtypes. <i>Nature genetics</i> 49, 1126-1132 (2017). Wen, W., <i>et al.</i> Genetic variations of DNA bindings of FOXA1 and co-factors in breast cancer susceptibility. <i>Nature communications</i> 12, 5318 (2021). Moreno, V., <i>et al.</i> Identifying Putative Susceptibility Genes and Evaluating Their Associations with Somatic Mutations in Human Cancers. <i>American journal of human genetics</i> 105, 477- 492 (2019). Chen, Z., <i>et al.</i> A Comprehensive cis-eQTL Analysis Revealed Target Genes in Breast Cancer Susceptibility. Loci Identifying Inscription factor occupancy with transcriptome-wide association analysis identifies susceptibility genes in human cancers. <i>Nature communic</i>	628		(2020).
 analysis of 100,204 cases and 154,587 controls of European and east Asian ancestries. <i>Nat</i> <i>Genet</i> 55, 89-99 (2023). Conti, D.V., <i>et al.</i> Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction. <i>Nature genetics</i> 53, 65-75 (2021). Byun, J., <i>et al.</i> Cross-ancestry genome-wide meta-analysis of 61,047 cases and 947,237 controls identifies new susceptibility loci contributing to lung cancer. <i>Nature genetics</i> 54, 1167-1177 (2022). Klein, A.P., <i>et al.</i> Genome-wide meta-analysis identifies five new susceptibility loci for pancreatic cancer. <i>Nat Commun</i> 9, 556 (2018). Phelan, C.M., <i>et al.</i> Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. <i>Nature genetics</i> 49, 680-691 (2017). Lawrenson, K., <i>et al.</i> Genome-wide association studies identify susceptibility loci for epithelial ovarian cancer in east Asian women. <i>Gynecol Oncol</i> 153, 343-355 (2019). McKay, J.D., <i>et al.</i> Large-scale association analysis identifies new lung cancer susceptibility loci and heterogeneity in genetic susceptibility across histological subtypes. <i>Nature genetics</i> 49, 1126-1132 (2017). Wen, W., <i>et al.</i> Genetic variations of DNA bindings of FOXA1 and co-factors in breast cancer susceptibility. <i>Nature communications</i> 12, 5318 (2021). Moreno, V., <i>et al.</i> A Comprehensive Cis-eQTL Analysis Revealed Target Genes in Breast Cancer Susceptibility. Loci Identified in Genome-wide Association Studies. <i>American Journal of human genetics</i> 102, 890-903 (2018). He, J., <i>et al.</i> Integrating transcription factor occupancy with transcriptome-wide association analysis identifies susceptibility genes for colorectal Cancer Risk From a Transcriptome-Wide Association Study of 125,478 Subjects. <i>Gastroenterology</i> 160, 1164- 1178 et1	629	7.	Fernandez-Rozadilla, C., et al. Deciphering colorectal cancer genetics through multi-omic
 <i>Genet</i> 55, 89-99 (2023). Conti, D.V., <i>et al.</i> Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction. <i>Nature genetics</i> 53, 65-75 (2021). Byun, J., <i>et al.</i> Cross-ancestry genome-wide meta-analysis of 61,047 cases and 947,237 controls identifies new susceptibility loci contributing to lung cancer. <i>Nature genetics</i> 54, 1167-1177 (2022). Klein, A.P., <i>et al.</i> Genome-wide meta-analysis identifies five new susceptibility loci for pancreatic cancer. <i>Nat Commun</i> 9, 556 (2018). Phelan, C.M., <i>et al.</i> Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. <i>Nature genetics</i> 49, 680-691 (2017). Lawrenson, K., <i>et al.</i> Genome-wide association studies identify susceptibility loci for epithelial ovarian cancer in east Asian women. <i>Gynecol Oncol</i> 153, 343-355 (2019). McKay, J.D., <i>et al.</i> Large-scale association analysis identifies new lung cancer susceptibility loci and heterogeneity in genetic susceptibility across histological subtypes. <i>Nature genetics</i> 49, 1126-1132 (2017). Wen, W., <i>et al.</i> Genetic variations of DNA bindings of FOXA1 and co-factors in breast cancer susceptibility. <i>Nature communications</i> 12, 5318 (2021). Moreno, V., <i>et al.</i> Colon-specific eQTL analysis to inform on functional SNPs. <i>Br J Cancer</i> 119, 971-977 (2018). Chen, Z., <i>et al.</i> Identifying Putative Susceptibility Genes and Evaluating Their Associations susceptibility. Loci Identified in Genome-wide Association Studies. <i>American journal of human genetics</i> 105, 477-492 (2019). He, J., <i>et al.</i> Integrating transcription factor occupancy with transcriptome-wide association sanalysis identifies association studies. <i>American journal of human genetics</i> 102, 890-903 (2018). He, J., <i>et al.</i> Integrating transcription factor occupancy with	630		analysis of 100,204 cases and 154,587 controls of European and east Asian ancestries. Nat
 8. Conti, D. V., <i>et al.</i> Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction. <i>Nature genetics</i> 53, 65- 75 (2021). 9. Byun, J., <i>et al.</i> Cross-ancestry genome-wide meta-analysis of 61,047 cases and 947,237 controls identifies new susceptibility loci contributing to lung cancer. <i>Nature genetics</i> 54, 1167-1177 (2022). 10. Klein, A.P., <i>et al.</i> Genome-wide meta-analysis identifies five new susceptibility loci for pancreatic cancer. <i>Nat Commun</i> 9, 556 (2018). 11. Phelan, C.M., <i>et al.</i> Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. <i>Nature genetics</i> 49, 680-691 (2017). 12. Lawrenson, K., <i>et al.</i> Genome-wide association studies identify susceptibility loci for epithelial ovarian cancer in east Asian women. <i>Gynecol Oncol</i> 153, 343-355 (2019). 13. McKay, J.D., <i>et al.</i> Large-scale association analysis identifies new lung cancer susceptibility loci and heterogeneity in genetic susceptibility across histological subtypes. <i>Nature genetics</i> 49, 1126-1132 (2017). 14. Wen, W., <i>et al.</i> Genetic variations of DNA bindings of FOXA1 and co-factors in breast cancer susceptibility. <i>Nature communications</i> 12, 5318 (2021). 15. Moreno, V., <i>et al.</i> Colon-specific eQTL analysis to inform on functional SNPs. Br J Cancer 119, 971-977 (2018). 16. Chen, Z., <i>et al.</i> Identifying Putative Susceptibility Genes and Evaluating Their Associations with Somatic Mutations in Human Cancers. <i>American journal of human genetics</i> 105, 477- 492 (2019). 18. He, J., <i>et al.</i> A Comprehensive cis-eQTL Analysis Revealed Target Genes in Breast Cancer Susceptibility Loci Identified in Genome-wide Association Studies. <i>American journal of human genetics</i> 102, 890-903 (2018). 18. He, J., <i>et al.</i> Identifying Novel Susceptibility Genes for Colorectal Cancer Risk From a Tra	631		Genet 55 , 89-99 (2023).
 identifies new susceptibility loci and informs genetic risk prediction. <i>Nature genetics</i> 53, 65-75 (2021). Byun, J., <i>et al.</i> Cross-ancestry genome-wide meta-analysis of 61,047 cases and 947,237 controls identifies new susceptibility loci contributing to lung cancer. <i>Nature genetics</i> 54, 1167-1177 (2022). Klein, A.P., <i>et al.</i> Genome-wide meta-analysis identifies five new susceptibility loci for pancreatic cancer. <i>Nat Commun</i> 9, 556 (2018). Phelan, C.M., <i>et al.</i> Genome-wide genetics 49, 680-691 (2017). Lawrenson, K., <i>et al.</i> Genome-wide association studies identify susceptibility loci for epithelial ovarian cancer. <i>Nature genetics</i> 49, 680-691 (2017). Lawrenson, K., <i>et al.</i> Genome-wide association studies identify susceptibility loci for epithelial ovarian cancer in east Asian women. <i>Gynecol Oncol</i> 153, 343-355 (2019). McKay, J.D., <i>et al.</i> Large-scale association analysis identifies new lung cancer susceptibility loci and heterogeneity in genetic susceptibility across histological subtypes. <i>Nature genetics</i> 49, 1126-1132 (2017). Wen, W., <i>et al.</i> Genotic variations of DNA bindings of FOXA1 and co-factors in breast cancer susceptibility. <i>Nature communications</i> 12, 5318 (2021). Moreno, V., <i>et al.</i> Colon-specific eQTL analysis to inform on functional SNPs. <i>Br J Cancer</i> 119, 971-977 (2018). Chen, Z., <i>et al.</i> A Comprehensive cis-eQTL Analysis Revealed Target Genes in Breast Cancer Susceptibility Loci Identified in Genome-wide Association Studies. <i>American journal of human genetics</i> 102, 890-903 (2018). He, J., <i>et al.</i> Identifying Novel Susceptibility Genes for Colorectal Cancer Risk From a Transcriptome-Wide Association Study of 125,478 Subjects. <i>Gastroenterology</i> 160, 1164-1178 e1166 (2021). Guo, X., <i>et al.</i> Identifying Novel Susceptibility Genes for colorectal Cancer Risk From a Transcriptome-Wide Association Study of 125,478 Subjects. <i>Gastroenterology</i> 160, 1164-1178 e1166 (2021). <!--</td--><td>632</td><td>8.</td><td>Conti. D.V., et al. Trans-ancestry genome-wide association meta-analysis of prostate cancer</td>	632	8.	Conti. D.V., et al. Trans-ancestry genome-wide association meta-analysis of prostate cancer
 75 (2021). Byun, J., et al. Cross-ancestry genome-wide meta-analysis of 61,047 cases and 947,237 controls identifies new susceptibility loci contributing to lung cancer. Nature genetics 54, 1167-1177 (2022). Klein, A.P., et al. Genome-wide meta-analysis identifies five new susceptibility loci for pancreatic cancer. Nature genetics 49, 680-691 (2017). Phelan, C.M., et al. Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. Nature genetics 49, 680-691 (2017). Lawrenson, K., et al. Genome-wide association studies identify susceptibility loci for epithelial ovarian cancer in east Asian women. Gynecol Oncol 153, 343-355 (2019). McKay, J.D., et al. Large-scale association analysis identifies new lung cancer susceptibility loci and hetrogeneity in genetic susceptibility across histological subtypes. Nature genetics 49, 1126-1132 (2017). Wen, W., et al. Genetic variations of DNA bindings of FOXA1 and co-factors in breast cancer susceptibility. Nature communications 12, 5318 (2021). Moreno, V., et al. Colon-specific eQTL analysis to inform on functional SNPs. Br J Cancer 119, 971-977 (2018). Chen, Z., et al. Identifying Putative Susceptibility Genes and Evaluating Their Associations with Somatic Mutations in Human Cancers. American journal of human genetics 105, 477-492 (2019). He, J., et al. A Comprehensive cis-eQTL Analysis Revealed Target Genes in Breast Cancer Susceptibility Loci Identified in Genome-wide Association Studies. American journal of human genetics 102, 890-903 (2018). He, J., et al. Integrating transcription factor occupancy with transcriptome-wide association analysis identifies susceptibility Genes for Colorectal Cancer Risk From a Transcriptome-Wide Association Study of 125,478 Subjects. Gastroenterology 160, 1164-1178 e1166 (2021). Yuan, Y., et al. Multi-omics analysis to identify susceptibility genes for colorectal cancer. Human molecul	633		identifies new susceptibility loci and informs genetic risk prediction. <i>Nature genetics</i> 53 . 65-
 9. Byun, J., et al. Cross-ancestry genome-wide meta-analysis of 61,047 cases and 947,237 controls identifies new susceptibility loci contributing to lung cancer. Nature genetics 54, 1167-1177 (2022). 10. Klein, A.P., et al. Genome-wide meta-analysis identifies five new susceptibility loci for pancreatic cancer. Nat Commun 9, 556 (2018). 11. Phelan, C.M., et al. Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. Nature genetics 49, 680-691 (2017). 12. Lawrenson, K., et al. Genome-wide association studies identify susceptibility loci for epithelial ovarian cancer in east Asian women. Gynecol Oncol 153, 343-355 (2019). 13. McKay, J.D., et al. Large-scale association analysis identifies new lung cancer susceptibility loci and heterogeneity in genetic susceptibility across histological subtypes. Nature genetics 49, 1126-1132 (2017). 14. Wen, W., et al. Genetic variations of DNA bindings of FOXA1 and co-factors in breast cancer susceptibility. Nature communications 12, 5318 (2021). 15. Moreno, V., et al. Colon-specific eQTL analysis to inform on functional SNPs. Br J Cancer 119, 971-977 (2018). 16. Chen, Z., et al. Identifying Putative Susceptibility Genes and Evaluating Their Associations with Somatic Mutations in Human Cancers. American journal of human genetics 105, 477-492 (2019). 17. Guo, X., et al. A Comprehensive cis-eQTL Analysis Revealed Target Genes in Breast Cancer Susceptibility Loci Identified in Genome-wide Association Studies. American journal of human genetics 102, 890-903 (2018). 18. He, J., et al. Integrating transcription factor occupancy with transcriptome-wide association analysis identifies susceptibility Genes for Colorectal Cancer Risk From a Transcriptome-Wide Association Study of 125,478 Subjects. Gastroenterology 160, 1164-1178 e1166 (2021). 19. Guo, X., et al. Identifying Novel Susceptibi	634		75 (2021).
 controls identifies new susceptibility loci contributing to lung cancer. <i>Nature genetics</i> 54, 1167-1177 (2022). 10. Klein, A.P., <i>et al.</i> Genome-wide meta-analysis identifies five new susceptibility loci for pancreatic cancer. <i>Nat Commun</i> 9, 556 (2018). 11. Phelan, C.M., <i>et al.</i> Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. <i>Nature genetics</i> 49, 680-691 (2017). 12. Lawrenson, K., <i>et al.</i> Genome-wide association studies identify susceptibility loci for epithelial ovarian cancer in east Asian women. <i>Gynecol Oncol</i> 153, 343-355 (2019). 13. McKay, J.D., <i>et al.</i> Large-scale association analysis identifies new lung cancer susceptibility loci and heterogeneity in genetic susceptibility across histological subtypes. <i>Nature genetics</i> 49, 1126-1132 (2017). 14. Wen, W., <i>et al.</i> Genetic variations of DNA bindings of FOXA1 and co-factors in breast cancer susceptibility. <i>Nature communications</i> 12, 5318 (2021). 15. Moreno, V., <i>et al.</i> Colon-specific eQTL analysis to inform on functional SNPs. <i>Br J Cancer</i> 119, 971-977 (2018). 16. Chen, <i>Z., et al.</i> Identifying Putative Susceptibility Genes and Evaluating Their Associations with Somatic Mutations in Human Cancers. <i>American journal of human genetics</i> 105, 477-492 (2019). 17. Guo, X., <i>et al.</i> A Comprehensive cis-eQTL Analysis Revealed Target Genes in Breast Cancer Susceptibility Loci Identified in Genome-wide Association Studies. <i>American journal of human genetics</i> 102, 800-903 (2018). 18. He, J., <i>et al.</i> Integrating transcription factor occupancy with transcriptome-wide association analysis identifies usceptibility Genes for Colorectal Cancer Risk From a Transcriptome-Wide Association Study of 125,478 Subjects. <i>Gastroenterology</i> 160, 1164-1178 e1166 (2021). 20. Yuan, Y., <i>et al.</i> Multi-omics analysis to identify susceptibility genes for colorectal cancer. <i>Human molecular genetics</i> 30, 321-330 (2021). 	635	9.	Byun, J., <i>et al.</i> Cross-ancestry genome-wide meta-analysis of 61.047 cases and 947.237
 1167-1177 (2022). Klein, A.P., <i>et al.</i> Genome-wide meta-analysis identifies five new susceptibility loci for pancreatic cancer. <i>Nat Commun</i> 9, 556 (2018). Phelan, C.M., <i>et al.</i> Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. <i>Nature genetics</i> 49, 680-691 (2017). Lawrenson, K., <i>et al.</i> Genome-wide association studies identify susceptibility loci for epithelial ovarian cancer in east Asian women. <i>Gynecol Oncol</i> 153, 343-355 (2019). McKay, J.D., <i>et al.</i> Large-scale association analysis identifies new lung cancer susceptibility loci and heterogeneity in genetic susceptibility across histological subtypes. <i>Nature genetics</i> 49, 1126-1132 (2017). Wen, W., <i>et al.</i> Colon-specific eQTL analysis to inform on functional SNPs. <i>Br J Cancer</i> 119, 971-977 (2018). Moreno, V., <i>et al.</i> Identifying Putative Susceptibility Genes and Evaluating Their Associations with Somatic Mutations in Human Cancers. <i>American journal of human genetics</i> 105, 477- 492 (2019). Guo, X., <i>et al.</i> A Comprehensive cis-eQTL Analysis Revealed Target Genes in Breast Cancer Susceptibility Loci Identified in Genome-wide Association Studies. <i>American journal of human genetics</i> 102, 890-903 (2018). He, J., <i>et al.</i> Integrating transcription factor occupancy with transcriptome-wide association analysis identifies susceptibility Genes for Colorectal Cancer Risk From a Transcriptome-Wide Association Study of 125,478 Subjects. <i>Gastroenterology</i> 160, 1164- 1178 e1166 (2021). Yuan, Y., <i>et al.</i> Multi-omics analysis to identify susceptibility genes for colorectal cancer. <i>Human molecular genetics</i> 30, 321-330 (2021). 	636		controls identifies new suscentibility loci contributing to lung cancer. <i>Nature genetics</i> 54
 Klein, A.P., et al. Genome-wide meta-analysis identifies five new susceptibility loci for pancreatic cancer. Nat Commun 9, 556 (2018). Phelan, C.M., et al. Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. Nature genetics 49, 680-691 (2017). Lawrenson, K., et al. Genome-wide association studies identify susceptibility loci for epithelial ovarian cancer in east Asian women. <i>Gynecol Oncol</i> 153, 343-355 (2019). McKay, J.D., et al. Large-scale association analysis identifies new lung cancer susceptibility loci and heterogeneity in genetic susceptibility across histological subtypes. Nature genetics 49, 1126-1132 (2017). Wen, W., et al. Genetic variations of DNA bindings of FOXA1 and co-factors in breast cancer susceptibility. Nature communications 12, 5318 (2021). Moreno, V., et al. Colon-specific eQTL analysis to inform on functional SNPs. Br J Cancer 119, 971-977 (2018). Chen, Z., et al. Identifying Putative Susceptibility Genes and Evaluating Their Associations with Somatic Mutations in Human Cancers. American journal of human genetics 105, 477- 492 (2019). Guo, X., et al. A Comprehensive cis-eQTL Analysis Revealed Target Genes in Breast Cancer Susceptibility Loci Identified in Genome-wide Association Studies. American journal of human genetics 102, 890-903 (2018). He, J., et al. Integrating transcription factor occupancy with transcriptome-wide association analysis identifies susceptibility Genes for Colorectal Cancer Risk From a Transcriptome-Wide Association Study of 125,478 Subjects. Gastroenterology 160, 1164- 1178 e1166 (2021). Yuan, Y., et al. Multi-omics analysis to identify susceptibility genes for colorectal cancer. Human molecular genetics 30, 321-330 (2021). 	637		1167-1177 (2022)
 har, Parti Strain Orthon Strain Commun 9, 556 (2018). pancreatic cancer. Nat Commun 9, 556 (2018). Phelan, C.M., et al. Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. Nature genetics 49, 680-691 (2017). Lawrenson, K., et al. Genome-wide association studies identify susceptibility loci for epithelial ovarian cancer in east Asian women. Gynecol Oncol 153, 343-355 (2019). McKay, J.D., et al. Large-scale association analysis identifies new lung cancer susceptibility loci and heterogeneity in genetic susceptibility across histological subtypes. Nature genetics 49, 1126-1132 (2017). Wen, W., et al. Genetic variations of DNA bindings of FOXA1 and co-factors in breast cancer susceptibility. Nature communications 12, 5318 (2021). Moreno, V., et al. Colon-specific eQTL analysis to inform on functional SNPs. Br J Cancer 119, 971-977 (2018). Chen, Z., et al. Identifying Putative Susceptibility Genes and Evaluating Their Associations with Somatic Mutations in Human Cancers. American journal of human genetics 105, 477- 492 (2019). Guo, X., et al. A Comprehensive cis-eQTL Analysis Revealed Target Genes in Breast Cancer Susceptibility Loci Identified in Genome-wide Association Studies. American journal of human genetics 102, 890-903 (2018). He, J., et al. Integrating transcription factor occupancy with transcriptome-wide association analysis identifies susceptibility genes in human cancers. Nature communications 13, 7118 (2022). Guo, X., et al. Identifying Novel Susceptibility Genes for Colorectal Cancer Risk From a Transcriptome-Wide Association Study of 125,478 Subjects. Gastroenterology 160, 1164- 1178 e1166 (2021). Yuan, Y., et al. Multi-omics analysis to identify susceptibility genes for colorectal cancer. Human molecular genetics 30, 321-330 (2021). 	638	10	Klein A P <i>et al.</i> Genome-wide meta-analysis identifies five new suscentibility loci for
 Phelan, C.M., <i>et al.</i> Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. <i>Nature genetics</i> 49, 680-691 (2017). Lawrenson, K., <i>et al.</i> Genome-wide association studies identify susceptibility loci for epithelial ovarian cancer in east Asian women. <i>Gynecol Oncol</i> 153, 343-355 (2019). McKay, J.D., <i>et al.</i> Large-scale association analysis identifies new lung cancer susceptibility loci and heterogeneity in genetic susceptibility across histological subtypes. <i>Nature genetics</i> 49, 1126-1132 (2017). Wen, W., <i>et al.</i> Genetic variations of DNA bindings of FOXA1 and co-factors in breast cancer susceptibility. <i>Nature communications</i> 12, 5318 (2021). Moreno, V., <i>et al.</i> Colon-specific eQTL analysis to inform on functional SNPs. <i>Br J Cancer</i> 119, 971-977 (2018). Chen, Z., <i>et al.</i> Identifying Putative Susceptibility Genes and Evaluating Their Associations with Somatic Mutations in Human Cancers. <i>American journal of human genetics</i> 105, 477- 492 (2019). Guo, X., <i>et al.</i> A Comprehensive cis-eQTL Analysis Revealed Target Genes in Breast Cancer Susceptibility Loci Identified in Genome-wide Association Studies. <i>American journal of</i> <i>human genetics</i> 102, 890-903 (2018). He, J., <i>et al.</i> Integrating transcription factor occupancy with transcriptome-wide association analysis identifies susceptibility genes in human cancers. <i>Nature communications</i> 13, 7118 (2022). Guo, X., <i>et al.</i> Identifying Novel Susceptibility Genes for Colorectal Cancer Risk From a Transcriptome-Wide Association Study of 125,478 Subjects. <i>Gastroenterology</i> 160, 1164- 1178 e1166 (2021). Yuan, Y., <i>et al.</i> Multi-omics analysis to identify susceptibility genes for colorectal cancer. <i>Human molecular genetics</i> 30, 321-330 (2021). 	639	10.	pancreatic cancer. Nat Commun 9, 556 (2018).
 epithelial ovarian cancer. <i>Nature genetics</i> 49, 680-691 (2017). Lawrenson, K., <i>et al.</i> Genome-wide association studies identify susceptibility loci for epithelial ovarian cancer in east Asian women. <i>Gynecol Oncol</i> 153, 343-355 (2019). McKay, J.D., <i>et al.</i> Large-scale association analysis identifies new lung cancer susceptibility loci and heterogeneity in genetic susceptibility across histological subtypes. <i>Nature genetics</i> 49, 1126-1132 (2017). Wen, W., <i>et al.</i> Genetic variations of DNA bindings of FOXA1 and co-factors in breast cancer susceptibility. <i>Nature communications</i> 12, 5318 (2021). Moreno, V., <i>et al.</i> Colon-specific eQTL analysis to inform on functional SNPs. <i>Br J Cancer</i> 119, 971-977 (2018). Chen, Z., <i>et al.</i> Identifying Putative Susceptibility Genes and Evaluating Their Associations with Somatic Mutations in Human Cancers. <i>American journal of human genetics</i> 105, 477-492 (2019). Guo, X., <i>et al.</i> A Comprehensive cis-eQTL Analysis Revealed Target Genes in Breast Cancer Susceptibility Loci Identified in Genome-wide Association Studies. <i>American journal of human genetics</i> 102, 890-903 (2018). He, J., <i>et al.</i> Integrating transcription factor occupancy with transcriptome-wide association analysis identifies susceptibility genes in human cancers. <i>Nature communications</i> 13, 7118 (2022). Guo, X., <i>et al.</i> Identifying Novel Susceptibility Genes for Colorectal Cancer Risk From a Transcriptome-Wide Association Study of 125,478 Subjects. <i>Gastroenterology</i> 160, 1164-1178 e1166 (2021). Yuan, Y., <i>et al.</i> Multi-omics analysis to identify susceptibility genes for colorectal cancer. <i>Human molecular genetics</i> 30, 321-330 (2021). 	640	11.	Phelan, C.M., et al. Identification of 12 new susceptibility loci for different histotypes of
 Lawrenson, K., et al. Genome-wide association studies identify susceptibility loci for epithelial ovarian cancer in east Asian women. <i>Gynecol Oncol</i> 153, 343-355 (2019). McKay, J.D., et al. Large-scale association analysis identifies new lung cancer susceptibility loci and heterogeneity in genetic susceptibility across histological subtypes. <i>Nature genetics</i> 49, 1126-1132 (2017). Wen, W., et al. Genetic variations of DNA bindings of FOXA1 and co-factors in breast cancer susceptibility. <i>Nature communications</i> 12, 5318 (2021). Moreno, V., et al. Colon-specific eQTL analysis to inform on functional SNPs. Br J Cancer 119, 971-977 (2018). Chen, Z., et al. Identifying Putative Susceptibility Genes and Evaluating Their Associations with Somatic Mutations in Human Cancers. <i>American journal of human genetics</i> 105, 477- 492 (2019). Guo, X., et al. A Comprehensive cis-eQTL Analysis Revealed Target Genes in Breast Cancer Susceptibility Loci Identified in Genome-wide Association Studies. <i>American journal of human genetics</i> 102, 890-903 (2018). He, J., et al. Integrating transcription factor occupancy with transcriptome-wide association analysis identifies susceptibility Genes for Colorectal Cancer Risk From a Transcriptome-Wide Association Study of 125,478 Subjects. <i>Gastroenterology</i> 160, 1164- 1178 e1166 (2021). Yuan, Y., et al. Multi-omics analysis to identify susceptibility genes for colorectal cancer. <i>Human molecular genetics</i> 30, 321-330 (2021). 	641		epithelial ovarian cancer. Nature genetics 49 , 680-691 (2017).
 epithelial ovarian cancer in east Asian women. <i>Gynecol Oncol</i> 153, 343-355 (2019). McKay, J.D., <i>et al.</i> Large-scale association analysis identifies new lung cancer susceptibility loci and heterogeneity in genetic susceptibility across histological subtypes. <i>Nature genetics</i> 49, 1126-1132 (2017). Wen, W., <i>et al.</i> Genetic variations of DNA bindings of FOXA1 and co-factors in breast cancer susceptibility. <i>Nature communications</i> 12, 5318 (2021). Moreno, V., <i>et al.</i> Colon-specific eQTL analysis to inform on functional SNPs. <i>Br J Cancer</i> 119, 971-977 (2018). Chen, Z., <i>et al.</i> Identifying Putative Susceptibility Genes and Evaluating Their Associations with Somatic Mutations in Human Cancers. <i>American journal of human genetics</i> 105, 477-492 (2019). Guo, X., <i>et al.</i> A Comprehensive cis-eQTL Analysis Revealed Target Genes in Breast Cancer Susceptibility Loci Identified in Genome-wide Association Studies. <i>American journal of human genetics</i> 102, 890-903 (2018). He, J., <i>et al.</i> Integrating transcription factor occupancy with transcriptome-wide association analysis identifies susceptibility genes in human cancers. <i>Nature communications</i> 13, 7118 (2022). Guo, X., <i>et al.</i> Identifying Novel Susceptibility Genes for Colorectal Cancer Risk From a Transcriptome-Wide Association Study of 125,478 Subjects. <i>Gastroenterology</i> 160, 1164-1178 e1166 (2021). Yuan, Y., <i>et al.</i> Multi-omics analysis to identify susceptibility genes for colorectal cancer. <i>Human molecular genetics</i> 30, 321-330 (2021). 	642	12.	Lawrenson, K., et al. Genome-wide association studies identify susceptibility loci for
 McKay, J.D., <i>et al.</i> Large-scale association analysis identifies new lung cancer susceptibility loci and heterogeneity in genetic susceptibility across histological subtypes. <i>Nature genetics</i> 49, 1126-1132 (2017). Wen, W., <i>et al.</i> Genetic variations of DNA bindings of FOXA1 and co-factors in breast cancer susceptibility. <i>Nature communications</i> 12, 5318 (2021). Moreno, V., <i>et al.</i> Colon-specific eQTL analysis to inform on functional SNPs. <i>Br J Cancer</i> 119, 971-977 (2018). Chen, Z., <i>et al.</i> Identifying Putative Susceptibility Genes and Evaluating Their Associations with Somatic Mutations in Human Cancers. <i>American journal of human genetics</i> 105, 477- 492 (2019). Guo, X., <i>et al.</i> A Comprehensive cis-eQTL Analysis Revealed Target Genes in Breast Cancer Susceptibility Loci Identified in Genome-wide Association Studies. <i>American journal of human genetics</i> 102, 890-903 (2018). He, J., <i>et al.</i> Integrating transcription factor occupancy with transcriptome-wide association analysis identifies susceptibility genes in human cancers. <i>Nature communications</i> 13, 7118 (2022). Guo, X., <i>et al.</i> Identifying Novel Susceptibility Genes for Colorectal Cancer Risk From a Transcriptome-Wide Association Study of 125,478 Subjects. <i>Gastroenterology</i> 160, 1164- 1178 e1166 (2021). Yuan, Y., <i>et al.</i> Multi-omics analysis to identify susceptibility genes for colorectal cancer. <i>Human molecular genetics</i> 30, 321-330 (2021). 	643		epithelial ovarian cancer in east Asian women. <i>Gynecol Oncol</i> 153 , 343-355 (2019).
 loci and heterogeneity in genetic susceptibility across histological subtypes. <i>Nature genetics</i> 49, 1126-1132 (2017). 14. Wen, W., <i>et al.</i> Genetic variations of DNA bindings of FOXA1 and co-factors in breast cancer susceptibility. <i>Nature communications</i> 12, 5318 (2021). 15. Moreno, V., <i>et al.</i> Colon-specific eQTL analysis to inform on functional SNPs. <i>Br J Cancer</i> 119, 971-977 (2018). 16. Chen, Z., <i>et al.</i> Identifying Putative Susceptibility Genes and Evaluating Their Associations with Somatic Mutations in Human Cancers. <i>American journal of human genetics</i> 105, 477-492 (2019). 17. Guo, X., <i>et al.</i> A Comprehensive cis-eQTL Analysis Revealed Target Genes in Breast Cancer Susceptibility Loci Identified in Genome-wide Association Studies. <i>American journal of human genetics</i> 102, 890-903 (2018). 18. He, J., <i>et al.</i> Integrating transcription factor occupancy with transcriptome-wide association analysis identifies susceptibility genes in human cancers. <i>Nature communications</i> 13, 7118 (2022). 19. Guo, X., <i>et al.</i> Identifying Novel Susceptibility Genes for Colorectal Cancer Risk From a Transcriptome-Wide Association Study of 125,478 Subjects. <i>Gastroenterology</i> 160, 1164-1178 e1166 (2021). 20. Yuan, Y., <i>et al.</i> Multi-omics analysis to identify susceptibility genes for colorectal cancer. <i>Human molecular genetics</i> 30, 321-330 (2021). 	644	13.	McKay, J.D., et al. Large-scale association analysis identifies new lung cancer susceptibility
 49, 1126-1132 (2017). Wen, W., <i>et al.</i> Genetic variations of DNA bindings of FOXA1 and co-factors in breast cancer susceptibility. <i>Nature communications</i> 12, 5318 (2021). Moreno, V., <i>et al.</i> Colon-specific eQTL analysis to inform on functional SNPs. <i>Br J Cancer</i> 119, 971-977 (2018). Chen, Z., <i>et al.</i> Identifying Putative Susceptibility Genes and Evaluating Their Associations with Somatic Mutations in Human Cancers. <i>American journal of human genetics</i> 105, 477-492 (2019). Guo, X., <i>et al.</i> A Comprehensive cis-eQTL Analysis Revealed Target Genes in Breast Cancer Susceptibility Loci Identified in Genome-wide Association Studies. <i>American journal of human genetics</i> 102, 890-903 (2018). He, J., <i>et al.</i> Integrating transcription factor occupancy with transcriptome-wide association analysis identifies susceptibility genes in human cancers. <i>Nature communications</i> 13, 7118 (2022). Guo, X., <i>et al.</i> Identifying Novel Susceptibility Genes for Colorectal Cancer Risk From a Transcriptome-Wide Association Study of 125,478 Subjects. <i>Gastroenterology</i> 160, 1164-1178 e1166 (2021). Yuan, Y., <i>et al.</i> Multi-omics analysis to identify susceptibility genes for colorectal cancer. <i>Human molecular genetics</i> 30, 321-330 (2021). 	645		loci and heterogeneity in genetic susceptibility across histological subtypes. Nature genetics
 Wen, W., et al. Genetic variations of DNA bindings of FOXA1 and co-factors in breast cancer susceptibility. Nature communications 12, 5318 (2021). Moreno, V., et al. Colon-specific eQTL analysis to inform on functional SNPs. Br J Cancer 119, 971-977 (2018). Chen, Z., et al. Identifying Putative Susceptibility Genes and Evaluating Their Associations with Somatic Mutations in Human Cancers. American journal of human genetics 105, 477- 492 (2019). Guo, X., et al. A Comprehensive cis-eQTL Analysis Revealed Target Genes in Breast Cancer Susceptibility Loci Identified in Genome-wide Association Studies. American journal of human genetics 102, 890-903 (2018). He, J., et al. Integrating transcription factor occupancy with transcriptome-wide association analysis identifies susceptibility genes in human cancers. Nature communications 13, 7118 (2022). Guo, X., et al. Identifying Novel Susceptibility Genes for Colorectal Cancer Risk From a Transcriptome-Wide Association Study of 125,478 Subjects. Gastroenterology 160, 1164- 1178 e1166 (2021). Yuan, Y., et al. Multi-omics analysis to identify susceptibility genes for colorectal cancer. Human molecular genetics 30, 321-330 (2021). 	646		49 , 1126-1132 (2017).
 susceptibility. <i>Nature communications</i> 12, 5318 (2021). Moreno, V., <i>et al.</i> Colon-specific eQTL analysis to inform on functional SNPs. <i>Br J Cancer</i> 119, 971-977 (2018). Chen, Z., <i>et al.</i> Identifying Putative Susceptibility Genes and Evaluating Their Associations with Somatic Mutations in Human Cancers. <i>American journal of human genetics</i> 105, 477-492 (2019). Guo, X., <i>et al.</i> A Comprehensive cis-eQTL Analysis Revealed Target Genes in Breast Cancer Susceptibility Loci Identified in Genome-wide Association Studies. <i>American journal of human genetics</i> 102, 890-903 (2018). He, J., <i>et al.</i> Integrating transcription factor occupancy with transcriptome-wide association analysis identifies susceptibility genes in human cancers. <i>Nature communications</i> 13, 7118 (2022). Guo, X., <i>et al.</i> Identifying Novel Susceptibility Genes for Colorectal Cancer Risk From a Transcriptome-Wide Association Study of 125,478 Subjects. <i>Gastroenterology</i> 160, 1164-1178 e1166 (2021). Yuan, Y., <i>et al.</i> Multi-omics analysis to identify susceptibility genes for colorectal cancer. <i>Human molecular genetics</i> 30, 321-330 (2021). 	647	14.	Wen, W., et al. Genetic variations of DNA bindings of FOXA1 and co-factors in breast cancer
 Moreno, V., et al. Colon-specific eQTL analysis to inform on functional SNPs. Br J Cancer 119, 971-977 (2018). Chen, Z., et al. Identifying Putative Susceptibility Genes and Evaluating Their Associations with Somatic Mutations in Human Cancers. American journal of human genetics 105, 477-492 (2019). Guo, X., et al. A Comprehensive cis-eQTL Analysis Revealed Target Genes in Breast Cancer Susceptibility Loci Identified in Genome-wide Association Studies. American journal of human genetics 102, 890-903 (2018). He, J., et al. Integrating transcription factor occupancy with transcriptome-wide association analysis identifies susceptibility genes in human cancers. Nature communications 13, 7118 (2022). Guo, X., et al. Identifying Novel Susceptibility Genes for Colorectal Cancer Risk From a Transcriptome-Wide Association Study of 125,478 Subjects. Gastroenterology 160, 1164-1178 e1166 (2021). Yuan, Y., et al. Multi-omics analysis to identify susceptibility genes for colorectal cancer. Human molecular genetics 30, 321-330 (2021). 	648		susceptibility. Nature communications 12 , 5318 (2021).
 971-977 (2018). 16. Chen, Z., et al. Identifying Putative Susceptibility Genes and Evaluating Their Associations with Somatic Mutations in Human Cancers. American journal of human genetics 105, 477- 492 (2019). 17. Guo, X., et al. A Comprehensive cis-eQTL Analysis Revealed Target Genes in Breast Cancer Susceptibility Loci Identified in Genome-wide Association Studies. American journal of human genetics 102, 890-903 (2018). 18. He, J., et al. Integrating transcription factor occupancy with transcriptome-wide association analysis identifies susceptibility genes in human cancers. Nature communications 13, 7118 (2022). 19. Guo, X., et al. Identifying Novel Susceptibility Genes for Colorectal Cancer Risk From a Transcriptome-Wide Association Study of 125,478 Subjects. Gastroenterology 160, 1164- 1178 e1166 (2021). 20. Yuan, Y., et al. Multi-omics analysis to identify susceptibility genes for colorectal cancer. Human molecular genetics 30, 321-330 (2021). 	649	15.	Moreno, V., et al. Colon-specific eOTL analysis to inform on functional SNPs. Br J Cancer 119.
 16. Chen, Z., et al. Identifying Putative Susceptibility Genes and Evaluating Their Associations with Somatic Mutations in Human Cancers. American journal of human genetics 105, 477- 492 (2019). 17. Guo, X., et al. A Comprehensive cis-eQTL Analysis Revealed Target Genes in Breast Cancer Susceptibility Loci Identified in Genome-wide Association Studies. American journal of human genetics 102, 890-903 (2018). 18. He, J., et al. Integrating transcription factor occupancy with transcriptome-wide association analysis identifies susceptibility genes in human cancers. Nature communications 13, 7118 (2022). 19. Guo, X., et al. Identifying Novel Susceptibility Genes for Colorectal Cancer Risk From a Transcriptome-Wide Association Study of 125,478 Subjects. Gastroenterology 160, 1164- 1178 e1166 (2021). 20. Yuan, Y., et al. Multi-omics analysis to identify susceptibility genes for colorectal cancer. Human molecular genetics 30, 321-330 (2021). 	650		971-977 (2018).
 with Somatic Mutations in Human Cancers. <i>American journal of human genetics</i> 105, 477-492 (2019). Guo, X., <i>et al.</i> A Comprehensive cis-eQTL Analysis Revealed Target Genes in Breast Cancer Susceptibility Loci Identified in Genome-wide Association Studies. <i>American journal of human genetics</i> 102, 890-903 (2018). He, J., <i>et al.</i> Integrating transcription factor occupancy with transcriptome-wide association analysis identifies susceptibility genes in human cancers. <i>Nature communications</i> 13, 7118 (2022). Guo, X., <i>et al.</i> Identifying Novel Susceptibility Genes for Colorectal Cancer Risk From a Transcriptome-Wide Association Study of 125,478 Subjects. <i>Gastroenterology</i> 160, 1164-1178 e1166 (2021). Yuan, Y., <i>et al.</i> Multi-omics analysis to identify susceptibility genes for colorectal cancer. <i>Human molecular genetics</i> 30, 321-330 (2021). 	651	16.	Chen, Z., et al. Identifying Putative Susceptibility Genes and Evaluating Their Associations
 492 (2019). 17. Guo, X., et al. A Comprehensive cis-eQTL Analysis Revealed Target Genes in Breast Cancer Susceptibility Loci Identified in Genome-wide Association Studies. American journal of human genetics 102, 890-903 (2018). 18. He, J., et al. Integrating transcription factor occupancy with transcriptome-wide association analysis identifies susceptibility genes in human cancers. Nature communications 13, 7118 (2022). Guo, X., et al. Identifying Novel Susceptibility Genes for Colorectal Cancer Risk From a Transcriptome-Wide Association Study of 125,478 Subjects. Gastroenterology 160, 1164- 1178 e1166 (2021). Yuan, Y., et al. Multi-omics analysis to identify susceptibility genes for colorectal cancer. Human molecular genetics 30, 321-330 (2021). 	652		with Somatic Mutations in Human Cancers. American journal of human genetics 105 . 477-
 Guo, X., et al. A Comprehensive cis-eQTL Analysis Revealed Target Genes in Breast Cancer Susceptibility Loci Identified in Genome-wide Association Studies. American journal of human genetics 102, 890-903 (2018). He, J., et al. Integrating transcription factor occupancy with transcriptome-wide association analysis identifies susceptibility genes in human cancers. Nature communications 13, 7118 (2022). Guo, X., et al. Identifying Novel Susceptibility Genes for Colorectal Cancer Risk From a Transcriptome-Wide Association Study of 125,478 Subjects. Gastroenterology 160, 1164- 1178 e1166 (2021). Yuan, Y., et al. Multi-omics analysis to identify susceptibility genes for colorectal cancer. Human molecular genetics 30, 321-330 (2021). 	653		492 (2019).
 Susceptibility Loci Identified in Genome-wide Association Studies. American journal of human genetics 102, 890-903 (2018). He, J., et al. Integrating transcription factor occupancy with transcriptome-wide association analysis identifies susceptibility genes in human cancers. Nature communications 13, 7118 (2022). Guo, X., et al. Identifying Novel Susceptibility Genes for Colorectal Cancer Risk From a Transcriptome-Wide Association Study of 125,478 Subjects. Gastroenterology 160, 1164- 1178 e1166 (2021). Yuan, Y., et al. Multi-omics analysis to identify susceptibility genes for colorectal cancer. Human molecular genetics 30, 321-330 (2021). 	654	17.	Guo, X., et al. A Comprehensive cis-eOTL Analysis Revealed Target Genes in Breast Cancer
 <i>human genetics</i> 102, 890-903 (2018). He, J., <i>et al.</i> Integrating transcription factor occupancy with transcriptome-wide association analysis identifies susceptibility genes in human cancers. <i>Nature communications</i> 13, 7118 (2022). Guo, X., <i>et al.</i> Identifying Novel Susceptibility Genes for Colorectal Cancer Risk From a Transcriptome-Wide Association Study of 125,478 Subjects. <i>Gastroenterology</i> 160, 1164- 1178 e1166 (2021). Yuan, Y., <i>et al.</i> Multi-omics analysis to identify susceptibility genes for colorectal cancer. <i>Human molecular genetics</i> 30, 321-330 (2021). 	655		Suscentibility Loci Identified in Genome-wide Association Studies. American journal of
 18. He, J., et al. Integrating transcription factor occupancy with transcriptome-wide association analysis identifies susceptibility genes in human cancers. Nature communications 13, 7118 (2022). 19. Guo, X., et al. Identifying Novel Susceptibility Genes for Colorectal Cancer Risk From a Transcriptome-Wide Association Study of 125,478 Subjects. Gastroenterology 160, 1164- 1178 e1166 (2021). 20. Yuan, Y., et al. Multi-omics analysis to identify susceptibility genes for colorectal cancer. Human molecular genetics 30, 321-330 (2021). 	656		human genetics 102 890-903 (2018)
 analysis identifies susceptibility genes in human cancers. <i>Nature communications</i> 13, 7118 (2022). Guo, X., et al. Identifying Novel Susceptibility Genes for Colorectal Cancer Risk From a Transcriptome-Wide Association Study of 125,478 Subjects. <i>Gastroenterology</i> 160, 1164- 1178 e1166 (2021). Yuan, Y., et al. Multi-omics analysis to identify susceptibility genes for colorectal cancer. <i>Human molecular genetics</i> 30, 321-330 (2021). 	657	18	He. L. et al. Integrating transcription factor occupancy with transcriptome-wide association
 659 (2022). 660 19. Guo, X., et al. Identifying Novel Susceptibility Genes for Colorectal Cancer Risk From a 661 Transcriptome-Wide Association Study of 125,478 Subjects. Gastroenterology 160, 1164- 662 1178 e1166 (2021). 663 20. Yuan, Y., et al. Multi-omics analysis to identify susceptibility genes for colorectal cancer. 664 Human molecular genetics 30, 321-330 (2021). 	658	10.	analysis identifies suscentibility genes in human cancers. <i>Nature communications</i> 13 7118
 660 19. Guo, X., et al. Identifying Novel Susceptibility Genes for Colorectal Cancer Risk From a 661 Transcriptome-Wide Association Study of 125,478 Subjects. Gastroenterology 160, 1164- 662 1178 e1166 (2021). 663 20. Yuan, Y., et al. Multi-omics analysis to identify susceptibility genes for colorectal cancer. 664 Human molecular genetics 30, 321-330 (2021). 	659		
 661 Transcriptome-Wide Association Study of 125,478 Subjects. <i>Gastroenterology</i> 160, 1164- 662 1178 e1166 (2021). 663 20. Yuan, Y., et al. Multi-omics analysis to identify susceptibility genes for colorectal cancer. 664 Human molecular genetics 30, 321-330 (2021). 	660	10	Guo X et al. Identifying Novel Suscentibility Genes for Colorectal Cancer Risk From a
 662 1178 e1166 (2021). 663 20. Yuan, Y., et al. Multi-omics analysis to identify susceptibility genes for colorectal cancer. 664 Human molecular genetics 30, 321-330 (2021). 	661	±9.	Transcriptome-Wide Association Study of 125 478 Subjects Gastroenterology 160 1164-
 663 20. Yuan, Y., <i>et al.</i> Multi-omics analysis to identify susceptibility genes for colorectal cancer. 664 <i>Human molecular genetics</i> 30. 321-330 (2021). 	667		1178 e1166 (2021)
664 Human molecular genetics 30 . 321-330 (2021).	663	20	Yuan Y et al. Multi-omics analysis to identify suscentibility genes for colorectal cancer
	664	20.	Human molecular genetics 30 , 321-330 (2021).

665	21.	Bien, S.A., et al. Genetic variant predictors of gene expression provide new insight into risk
666		of colorectal cancer. <i>Hum Genet</i> 138 , 307-326 (2019).
667	22.	Wu, L., et al. A transcriptome-wide association study of 229,000 women identifies new
668		candidate susceptibility genes for breast cancer. <i>Nature genetics</i> 50 , 968-978 (2018).
669	23.	Gao, G., et al. A joint transcriptome-wide association study across multiple tissues identifies
6/0	~ .	candidate breast cancer susceptibility genes. Am J Hum Genet 110 , 950-962 (2023).
6/1	24.	Mancuso, N., et al. Large-scale transcriptome-wide association study identifies new prostate
672	25	cancer risk regions. <i>Nature communications</i> 9 , 4079 (2018).
0/3	25.	Liu, D., et al. A transcriptome-wide association study identifies novel candidate susceptibility
0/4 675	26	genes for prostate cancer risk. Int J Cancer 150 , 80-90 (2022).
0/J 676	26.	Bosse, Y., et al. Transcriptome-wide association study reveals candidate causal genes for
0/0 677	27	Tung cancer. International journal of cancer 146 , 1862-1878 (2020).
0// 679	27.	Lu, Y., et al. A Transcriptome-wide Association Study Among 97,898 Women to Identify
078 670		Candidate Susceptibility Genes for Epitheliai Ovarian Cancer Risk. Curicer research 78 , 5419-
680	20	5450 (2016). Curay A at al. A transcriptoma wide association study of high grade serious onithelial
681	20.	Gusev, A., et al. A transcriptome-wide association study of high-grade serous epithelia
682		915 922 (2010)
683	20	7 or a l at al A Transcriptome-Wide Association Study Identifies Novel Candidate
68/	29.	Susceptibility Genes for Pancreatic Cancer / Natl Cancer Inst 112 1002-1012 (2020)
685	30	Zhang C L Han L V Van C W Ji Z L Cao Z W & Chan V Z Therapeutic targets: Progress
686	50.	of their exploration and investigation of their characteristics (vol 58, ng 259, 2006)
687		Pharmacol Rev 58, 682-682 (2006)
688	31	7hu Let al. Associations between Genetically Predicted Blood Protein Biomarkers and
689	51.	Pancreatic Cancer Risk Cancer enidemiology hiomarkers & prevention : a publication of the
690		American Association for Cancer Research, cosponsored by the American Society of
691		Preventive Oncology 29 , 1501-1508 (2020)
692	32.	Shu, X., et al. Evaluation of associations between genetically predicted circulating protein
693	•=-	biomarkers and breast cancer risk. International journal of cancer 146 , 2130-2138 (2020).
694	33.	Wu, L., et al. Analysis of Over 140.000 European Descendants Identifies Genetically
695		Predicted Blood Protein Biomarkers Associated with Prostate Cancer Risk. Cancer research
696		79 , 4592-4598 (2019).
697	34.	Gregga, I., et al. Predicted proteome association studies of breast, prostate, ovarian, and
698		endometrial cancers implicate plasma protein regulation in cancer susceptibility. <i>Cancer</i>
699		Epidemiol Biomarkers Prev (2023).
700	35.	Jia, G., et al. Identification of target proteins for breast cancer genetic risk loci and blood risk
701		biomarkers in a large study by integrating genomic and proteomic data. Int J Cancer 152,
702		2314-2320 (2023).
703	36.	Considine, D.P.C., et al. Genetically predicted circulating protein biomarkers and ovarian
704		cancer risk. <i>Gynecol Oncol</i> 160 , 506-513 (2021).
705	37.	Sun, B.B., et al. Plasma proteomic associations with genetics and health in the UK Biobank.
706		Nature (2023).
707	38.	Tautermann, C.S. Current and Future Challenges in Modern Drug Discovery. Methods Mol
708		<i>Biol</i> 2114 , 1-17 (2020).
709	39.	Pushpakom, S., et al. Drug repurposing: progress, challenges and recommendations. Nat Rev
710		Drug Discov 18 , 41-58 (2019).
711	40.	Zang, C., et al. High-throughput target trial emulation for Alzheimer's disease drug
712		repurposing with real-world data. <i>Nature communications</i> 14 , 8180 (2023).
713	41.	Wu, Y., et al. Discovery of Noncancer Drug Effects on Survival in Electronic Health Records of
714		Patients With Cancer: A New Paradigm for Drug Repurposing. JCO Clin Cancer Inform 3, 1-9
715		(2019).

716 717 718	42.	Xu, H., <i>et al.</i> Validating drug repurposing signals using electronic health records: a case study of metformin associated with reduced cancer mortality. <i>J Am Med Inform Assoc</i> 22 , 179-191 (2015)
710	10	Reian C.A. Cabill K.N. Staco D.L. Choi L. Datarcon J.E. & Dhilling E.L. DrugWAS: Drug wide
719	45.	Association Studios for COVID 10 Drug Donurnosing <i>Clin Dharmasol Thar</i> 110 1527 1546
720		
721		(2021).
722	44.	Biochem Biophys Res Commun 538, 173-179 (2021).
724 725	45.	Liu, R., Wei, L. & Zhang, P. A deep learning framework for drug repurposing via emulating clinical trials on real-world patient data. <i>Nat Mach Intell</i> 3 , 68-75 (2021).
726	46.	Zhang, J., et al. Plasma proteome analyses in individuals of European and African ancestry
727		identify cis-pQTLs and models for proteome-wide association studies. Nat Genet 54, 593-602
728		(2022).
729	47.	Ferkingstad, E., et al. Large-scale integration of the plasma proteome with genetics and
730		disease. Nat Genet 53, 1712-1721 (2021).
731	48.	Wang, G., Sarkar, A., Carbonetto, P. & Stephens, M. A simple new approach to variable
732		selection in regression, with application to genetic fine mapping. J R Stat Soc Series B Stat
733		Methodol 82 , 1273-1300 (2020)
734	49	Law V et al. DrugBank 4.0: shedding new light on drug metabolism Nucleic Acids Res 47
735	45.	
736	50	Gaulton A et al ChEMBL: a large-scale bioactivity database for drug discovery Nucleic
737	50.	acids research 40 D1100-1107 (2012)
738	51	Zhou V et al. TTD: Therapeutic Target Database describing target druggability information
730	51.	Nucleic Acids Res (2022)
740	52	Ochop D et al. The next-generation Open Targets Platform: reimagined redesigned
740	52.	rebuilt Nucleic Acids Res 51 D1353-D1359 (2023)
742	53	Chesnave NC et al. An introduction to inverse probability of treatment weighting in
743	55.	observational research Clin Kidney 115 14-20 (2022)
744	54	Eachal L et al Fine-manning of 150 breast cancer risk regions identifies 191 likely target
745	54.	genes Nature genetics 52 56-73 (2020)
746	55	Chen 7 et al. Fine-manning analysis including over 254 000 Fact Asian and European
7+0 7/7	55.	descendants identifies 126 putative colorectal cancer suscentibility games. Nat Commun 15
747		2557 (2024)
740	56	Successful Succes
750	50.	subtypes: a Mondelian randomication analysis. <i>Br J Cancer</i> 127 , 1507, 1514 (2022)
750	67	Subtypes: a Mendenan fandomisation analysis. <i>Bi J Cuncer</i> 127 , 1507-1514 (2022).
751	57.	Sun, J., <i>et al.</i> Identification of novel protein biomarkers and drug targets for colorectal
132 752	F 0	Cancer by Integrating numan plasma proteome with genome. <i>Genome Med</i> 15 (2023).
155	58.	Balley, M.H., et al. Comprehensive Characterization of Cancer Driver Genes and Mutations.
154 755	50	<i>Cell</i> 1/4 , 1034-1035 (2018).
100	59.	Dietiein, F., et al. Identification of cancer driver genes based on nucleotide context. Nature
/56		genetics 52 , 208-218 (2020).
757	60.	Sondka, Z., Bamford, S., Cole, C.G., Ward, S.A., Dunham, I. & Forbes, S.A. The COSMIC Cancer
758		Gene Census: describing genetic dysfunction across all human cancers. <i>Nat Rev Cancer</i> 18,
759		696-705 (2018).
760	61.	Austin, P.C. & Stuart, E.A. Moving towards best practice when using inverse probability of
761		treatment weighting (IPTW) using the propensity score to estimate causal treatment effects
762		in observational studies. <i>Stat Med</i> 34 , 3661-3679 (2015).
763	62.	Taipale, H., Solmi, M., Lahteenvuo, M., Tanskanen, A., Correll, C.U. & Tiihonen, J.
764		Antipsychotic use and risk of breast cancer in women with schizophrenia: a nationwide
765		nested case-control study in Finland. <i>Lancet Psychiatry</i> 8 , 883-891 (2021).

766	62	Wu G at all Targeting Case /TAM in cancer cells and tumor microenvironment. Mel Cancer
700	05.	17 20 (2010)
101	C A	17, 20 (2018).
/08	64.	Jansen, F.H., et al. Profiling of antibody production against xenograft-released proteins by
/69	65	protein microarrays discovers prostate cancer markers. J Proteome Res 11, 728-735 (2012).
//0	65.	Chiang, J.Y., et al. Haloperidol Instigates Endometrial Carcinogenesis and Cancer Progression
//1	~~	by the NF-kappaB/CSF-1 Signaling Cascade. <i>Cancers (Basel)</i> 14 (2022).
112	66.	Hippisley-Cox, J., Vinogradova, Y., Coupland, C. & Parker, C. Risk of malignancy in patients
773		with schizophrenia or bipolar disorder: nested case-control study. Arch Gen Psychiatry 64,
//4		1368-1376 (2007).
775	67.	Koh, S.L., Ager, E.I., Costa, P.L., Malcontenti-Wilson, C., Muralidharan, V. & Christophi, C.
776		Blockade of the renin-angiotensin system inhibits growth of colorectal cancer liver
777		metastases in the regenerating liver. <i>Clin Exp Metastasis</i> 31 , 395-405 (2014).
778	68.	Childers, W.K. Interactions of the renin-angiotensin system in colorectal cancer and
779		metastasis. Int J Colorectal Dis 30 , 749-752 (2015).
780	69.	Riddiough, G.E., et al. Captopril, a Renin-Angiotensin System Inhibitor, Attenuates Features
781		of Tumor Invasion and Down-Regulates C-Myc Expression in a Mouse Model of Colorectal
782		Cancer Liver Metastasis. Cancers (Basel) 13(2021).
783	70.	Kristensen, K.B., Hicks, B., Azoulay, L. & Pottegard, A. Use of ACE (Angiotensin-Converting
784		Enzyme) Inhibitors and Risk of Lung Cancer: A Nationwide Nested Case-Control Study. Circ
785		Cardiovasc Qual Outcomes 14, e006687 (2021).
786	71.	Yarmolinsky, J., et al. Genetically proxied therapeutic inhibition of antihypertensive drug
787		targets and risk of common cancers: A mendelian randomization analysis. PLoS Med 19,
788		e1003897 (2022).
789	72.	Karakus, F., Eyol, E., Yilmaz, K. & Unuvar, S. Inhibition of cell proliferation, migration and
790		colony formation of LS174T Cells by carbonic anhydrase inhibitor. Afr Health Sci 18, 1303-
791		1310 (2018).
792	73.	Noma, N., et al. Impact of Acetazolamide, a Carbonic Anhydrase Inhibitor, on the
793		Development of Intestinal Polyps in Min Mice. Int J Mol Sci 18(2017).
794	74.	Schmit, S.L., Rennert, H.S., Rennert, G., Gruber, S.B.J.C.E., Biomarkers & Prevention. Coffee
795		consumption and the risk of colorectal cancer. 25 , 634-639 (2016).
796	75.	Sartini, M., et al. Coffee Consumption and Risk of Colorectal Cancer: A Systematic Review
797		and Meta-Analysis of Prospective Studies. Nutrients 11 (2019).
798	76.	Um, C.Y., McCullough, M.L., Guinter, M.A., Campbell, P.T., Jacobs, E.J. & Gapstur, S.M.
799		Coffee consumption and risk of colorectal cancer in the Cancer Prevention Study-II Nutrition
800		Cohort. <i>Cancer Epidemiol</i> 67 , 101730 (2020).
801	77.	Micek, A., Gniadek, A., Kawalec, P. & Brzostek, T. Coffee consumption and colorectal cancer
802		risk: a dose-response meta-analysis on prospective cohort studies. Int J Food Sci Nutr 70,
803		986-1006 (2019).
804	78.	Schumacher, F.R., et al. Association analyses of more than 140,000 men identify 63 new
805		prostate cancer susceptibility loci. Nature genetics 50, 928-936 (2018).
806	79.	Huyghe, J.R., et al. Discovery of common and rare genetic risk variants for colorectal cancer.
807		Nature genetics 51 , 76-87 (2019).
808	80.	Chen, Z., et al. Novel insights into genetic susceptibility for colorectal cancer from
809		transcriptome-wide association and functional investigation. J Natl Cancer Inst 116, 127-137
810		(2024).
811	81.	Roden, D.M., et al. Development of a large-scale de-identified DNA biobank to enable
812		personalized medicine. Clin Pharmacol Ther 84, 362-369 (2008).
813	82.	Weissbrod, O., et al. Functionally informed fine-mapping and polygenic localization of
814		complex trait heritability. <i>Nat Genet</i> 52 , 1355-1363 (2020).
815	83.	Schwarzer, G., Carpenter, J.R. & Rücker, G. Meta-analysis with R, (Springer, 2015).

816 84. Giambartolomei, C., et al. Bayesian test for colocalisation between pairs of genetic 817 association studies using summary statistics. PLoS genetics 10, e1004383 (2014). 818 Zhu, Z., et al. Integration of summary data from GWAS and eQTL studies predicts complex 85. 819 trait gene targets. Nat Genet 48, 481-487 (2016). 820 Li, L., et al. An atlas of alternative polyadenylation quantitative trait loci contributing to 86. 821 complex trait and disease heritability. Nature genetics 53, 994-1005 (2021). 822 87. Ward, L.D. & Kellis, M. HaploReg: a resource for exploring chromatin states, conservation, 823 and regulatory motif alterations within sets of genetically linked variants. Nucleic Acids Res 824 40, D930-934 (2012). 825 He, B., Chen, C., Teng, L. & Tan, K. Global view of enhancer-promoter interactome in human 88. 826 cells. Proceedings of the National Academy of Sciences of the United States of America 111, 827 E2191-2199 (2014). 828 Lizio, M., et al. Gateways to the FANTOM5 promoter level mammalian expression atlas. 89. 829 Genome Biol 16, 22 (2015). 830 90. Gao, T. & Qian, J. EnhancerAtlas 2.0: an updated resource with enhancer annotation in 586 831 tissue/cell types across nine species. Nucleic acids research 48, D58-D64 (2020). 832 91. Wang, Y., et al. SEdb 2.0: a comprehensive super-enhancer database of human and mouse. 833 Nucleic Acids Res 51, D280-D290 (2023). 834 92. Chandrashekar, D.S., et al. UALCAN: A Portal for Facilitating Tumor Subgroup Gene 835 Expression and Survival Analyses. Neoplasia 19, 649-658 (2017). 836 93. Chandrashekar, D.S., et al. UALCAN: An update to the integrated cancer data analysis 837 platform. Neoplasia 25, 18-27 (2022). 838 94. Lin, D.Y. & Wei, L.-J. The robust inference for the Cox proportional hazards model. J Am Stat 839 Assoc 84, 1074-1078 (1989).

841 Figures

842 Fig. 1: Overview of the Analytical Framework.

- 843 a. An illustration depicting the identification of proteins associated with the risk of the six 844 major cancers: breast, lung, colorectal, ovarian, pancreatic, and prostate. Population-based 845 proteomics data (for pQTLs) and GWAS data resources (for identifying lead variants) utilized 846 in this study are shown in the left panels. Meta-analyses of *cis*-pQTLs from ARIC and 847 deCODE, conducted through the SOMAscan® platform, were combined with pQTL results 848 from the UKB-PPP to identify potential risk proteins, as depicted in the middle panels. 849 Colocalization analyses between GWAS summary statistics and *cis*-pQTLs were performed 850 to identify cancer risk proteins with high confidence, as illustrated in the right panel. b. The 851 proteins with evidence of colocalization annotated based on drug-protein information from 852 four databases: DrugBank, ChEMBL, TTD, and OpenTargets. c, The framework for 853 evaluating the effects of drugs approved for indications on cancer risk. The Inverse
- 854 Probability of Treatment weighting (IPTW) framework was utilized to construct emulations of
- treated-control drug trials based on millions of patients' Electronic Health Records stored at
 VUMC SD (left pane). In these emulations, the Cox proportional hazard model was
- 857 conducted for each trial to assess the hazard ratio (HR) of cancer risk between the treated
- focal drug and the control drug (right panels).
- 859

860 Fig.2: Genome-wide distribution of lead variants and putative risk proteins among six

- types of cancer. Proteins identified for each cancer are represented by different colors.
- 862 Each circle represents a single lead variant-protein pair. Proteins marked with an asterisk (*)
- denote multiple proteins associated with the lead variants. A dashed box highlights several
- 864 well-known cancer-related proteins, such as HLA-A and HLA-E, which are linked to lead
- variants located in the major histocompatibility complex (MHC).
- 866

Fig. 3: Identification of 101 cancer risk proteins through pQTL and colocalizationanalysis

- 869 **a**, Number of proteins showing evidence of colocalizations between pQTLs and GWAS
- 870 association signals for six cancer types. b, Percentage of proteins showing evidence of
- 871 colocalizations between pQTLs and GWAS summary statistics for six cancer types.
- 872 **c**, A plot illustrating the high consistency of pQTL p-values for 22 cancer risk proteins
- 873 between the ARIC+deCODE and the UKB-PPP (proteins commonly assays from
- 874 SOMAscan[®] and Olink platforms).
- 875

Fig. 4: A circular plot showing 36 druggable proteins potentially targeted by 404

877 approved drugs or undergoing clinical trials for cancer treatment or other indications

- 878 Presented from inner to outer layers are cancer types, proteins, and drugs. Each drug-
- protein interaction is annotated by DrugBank, ChEMBL, TTD, and OpenTargets, with lines in
 different colors representing each database. Interactions where proteins are annotated by
- two databases are linked to drugs with thick lines.
- 882

Fig. 5: A circular plot showing 19 druggable proteins potentially targeted by 133

approved drugs or undergoing clinical trials for cancer treatment. Presented from inner

- to outer layers are cancer types, proteins, drugs and cancers. Drugs approved and
- undergoing clinical trials for cancer treatment are highlighted on green and gray,
- respectively. Drug approved indications are formatted in bold, while indications under clinicaltrial are in regular font.
- 889

Fig. 6: Drugs approved for treated indications showing significant effects on cancerrisk

- 892 **a**, A table showing cancer risk alleles of lead variants, risk proteins, and drug name
- 893 approved for indications. Positive associations are indicated by upward arrows, while
- 894 negative associations are indicated by downward arrows. **b**, Boxplots showing differentially
- 895 expressed proteins between normal and tumor colon tissues using data from CPTAC.
- 896 **c**, An illustration of drugs linked to specific cancers based on the risk proteins targeted by
- the drugs. d, Survival plots depict the statistically significant difference in the probability of
- being cancer-free for patients in the treated group (taking a focal drug, shown in green)
- compared to control groups (shown in purple). The shaded area represents the 95%
- 900 confidence interval. The overall hazard ratio and P-value for the focal drug, determined
- 901 through Cox proportional hazard models, are presented in the top right corner of each panel.
- 902

903 Extended Data Fig. 1: A flowchart for characterizing lead variants with independent

- 904 **risk signals in six cancer types.** The analysis for each of the six major cancers: breast,
- 905 lung, colorectal, ovarian, pancreatic, and prostate is separated by dashed lines. The detailed
- 906 protocols of new efforts from our additional fine-mapping analysis using SuSiE and a
- 907 collection of previously identified risk variants from GWAS or fine-mapping studies are
- 908 indicated in Box A, Box B and Box C, respectively.
- 909

910 Extended Data Fig. 2: Common cancer risk proteins identified across six cancer types

- 911 **a**, A Venn plot showing common proteins in breast, colorectal, lung and prostate cancer. **b**,
- 912 A heatmap showing common proteins observed from at least two of six types of cancer.
- 913

914 Extended Data Fig. 3: A circular plot showing 28 druggable proteins potentially

915 targeted by 197 approved drugs or undergoing clinical trials for treated indications

- 916 rather than cancers. Presented from inner to outer layers are cancer types, proteins, drugs
- 917 and cancers. Drugs approved and undergoing clinical trials for cancer treatment are
- 918 highlighted on blue and gray, respectively. Drug approved indications are formatted in bold,
- 919 while indications under clinical trial are in regular font.
- 920



















Common proteins identified in at least two cancers



